Filed by Bowne Pure Compliance
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2008
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 1-14316
APRIA HEALTHCARE GROUP INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
33-0488566 |
(State or Other Jurisdiction of
|
|
(I.R.S. Employer |
Incorporation or Organization)
|
|
Identification Number) |
|
|
|
26220 Enterprise Court, Lake Forest, CA
|
|
92630 |
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number: (949) 639-2000
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large Accelerated Filer þ
|
|
Accelerated Filer o
|
|
Non-Accelerated Filer o
|
|
Smaller Reporting Company o |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
As
of September 10, 2008, there were outstanding 43,949,271 shares of the Registrants common
stock, par value $.001 per share, which is the only class of common stock of the Registrant (not
including 17,112,574 shares held in treasury).
APRIA HEALTHCARE GROUP INC.
FORM 10-Q
For the period ended June 30, 2008
2
Cautionary statement for purposes of the Safe Harbor provisions of the Private Securities
Litigation Reform Act of 1995: Our business is subject to a number of risks which are partly or
entirely beyond our control. We have described certain of those risks in our Annual Report on Form
10-K/A for the fiscal year ended December 31, 2007, as filed with the Securities and Exchange
Commission on February 29, 2008. That report, as supplemented by the information set forth in this
Quarterly Report on Form 10-Q, including Part II, Item 1A, Risk Factors, may be used for purposes
of the Private Securities Litigation Reform Act of 1995 as a readily available document containing
meaningful cautionary statements identifying important factors that could cause actual results to
differ materially from those projected in any forward-looking statements we may make from time to
time. In some cases, forward-looking statements contain terminology such as may, should,
could, expect, intend, plan, anticipate, believe, estimate, predict, potential,
or continue or variations of these terms or other comparable terminology. Key factors that may
have an impact on us include the following:
|
|
trends and developments affecting the collectibility of accounts receivable; |
|
|
|
government legislative and budget developments that could continue to affect reimbursement
levels; |
|
|
|
potential reductions in reimbursement rates by government and third-party payors; |
|
|
|
the effectiveness of our operating systems and controls; |
|
|
|
healthcare reform and the effect of federal and state healthcare regulations; |
|
|
|
economic and political events, international conflicts and natural disasters; |
|
|
|
acquisition-related risks; |
|
|
|
the failure to complete the proposed merger described herein; and |
|
|
|
other factors described in our filings with the Securities and Exchange Commission. |
3
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
APRIA HEALTHCARE GROUP INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Dollars in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
|
|
2008 |
|
|
2007 |
|
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
23,061 |
|
|
$ |
28,451 |
|
Accounts
receivable, less allowance for doubtful accounts of $32,962
and $47,823 at June 30, 2008 and December 31, 2007, respectively |
|
|
296,199 |
|
|
|
284,141 |
|
Inventories, net |
|
|
49,515 |
|
|
|
52,079 |
|
Deferred income taxes |
|
|
49,692 |
|
|
|
66,198 |
|
Deferred expenses |
|
|
2,908 |
|
|
|
3,102 |
|
Prepaid expenses and other current assets |
|
|
14,456 |
|
|
|
23,364 |
|
|
|
|
|
|
|
|
TOTAL CURRENT ASSETS |
|
|
435,831 |
|
|
|
457,335 |
|
PATIENT SERVICE EQUIPMENT, less accumulated depreciation of $438,843 and
$453,324 at June 30, 2008 and December 31, 2007, respectively |
|
|
204,971 |
|
|
|
200,180 |
|
PROPERTY, EQUIPMENT AND IMPROVEMENTS, net |
|
|
120,503 |
|
|
|
102,827 |
|
GOODWILL |
|
|
715,120 |
|
|
|
715,235 |
|
INTANGIBLE
ASSETS, less accumulated amortization of $9,263 and $7,907 at June
30, 2008 and December 31, 2007, respectively |
|
|
105,683 |
|
|
|
107,757 |
|
DEFERRED DEBT ISSUANCE COSTS, net |
|
|
5,025 |
|
|
|
2,834 |
|
OTHER ASSETS |
|
|
13,395 |
|
|
|
11,634 |
|
|
|
|
|
|
|
|
|
|
$ |
1,600,528 |
|
|
$ |
1,597,802 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
129,166 |
|
|
$ |
120,360 |
|
Accrued payroll and related taxes and benefits |
|
|
62,468 |
|
|
|
66,625 |
|
Income taxes payable |
|
|
1,249 |
|
|
|
3,076 |
|
Other accrued liabilities |
|
|
74,873 |
|
|
|
73,835 |
|
Deferred revenue |
|
|
30,471 |
|
|
|
29,704 |
|
Current portion of long-term debt |
|
|
253,806 |
|
|
|
254,252 |
|
|
|
|
|
|
|
|
TOTAL CURRENT LIABILITIES |
|
|
552,033 |
|
|
|
547,852 |
|
LONG-TERM DEBT, net of current portion |
|
|
371,184 |
|
|
|
433,031 |
|
DEFERRED INCOME TAXES |
|
|
80,646 |
|
|
|
62,290 |
|
INCOME TAXES PAYABLE AND OTHER NON-CURRENT LIABILITIES |
|
|
34,711 |
|
|
|
42,604 |
|
|
|
|
|
|
|
|
TOTAL LIABILITIES |
|
|
1,038,574 |
|
|
|
1,085,777 |
|
COMMITMENTS AND CONTINGENCIES (Note 12) |
|
|
|
|
|
|
|
|
STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Preferred stock, $.001 par value: 10,000,000 shares authorized; none issued |
|
|
|
|
|
|
|
|
Common stock, $.001 par value: 150,000,000 shares authorized; 61,043,341
and 60,844,901 shares issued at June 30, 2008 and December 31, 2007,
respectively; 43,935,741 and 43,794,492 shares outstanding at June 30,
2008 and December 31, 2007, respectively |
|
|
61 |
|
|
|
61 |
|
Additional paid-in capital |
|
|
522,175 |
|
|
|
514,848 |
|
Treasury stock, at cost; 17,107,600 and 17,050,409 shares at June 30, 2008
and December 31, 2007, respectively |
|
|
(432,915 |
) |
|
|
(431,651 |
) |
Retained earnings |
|
|
472,464 |
|
|
|
428,538 |
|
Accumulated other comprehensive income |
|
|
169 |
|
|
|
229 |
|
|
|
|
|
|
|
|
TOTAL STOCKHOLDERS EQUITY |
|
|
561,954 |
|
|
|
512,025 |
|
|
|
|
|
|
|
|
|
|
$ |
1,600,528 |
|
|
$ |
1,597,802 |
|
|
|
|
|
|
|
|
See notes to unaudited condensed consolidated financial statements.
4
APRIA HEALTHCARE GROUP INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
June 30, |
|
(in thousands, except per share data) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
|
|
|
|
(As Restated |
|
|
|
|
|
|
(As Restated |
|
|
|
|
|
|
|
See Note 3) |
|
|
|
|
|
|
See Note 3) |
|
Net revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fee for service/product arrangements |
|
$ |
488,078 |
|
|
$ |
350,619 |
|
|
$ |
973,434 |
|
|
$ |
700,114 |
|
Capitation arrangements |
|
|
43,170 |
|
|
|
41,310 |
|
|
|
85,792 |
|
|
|
82,594 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL NET REVENUES |
|
|
531,248 |
|
|
|
391,929 |
|
|
|
1,059,226 |
|
|
|
782,708 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of net revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product and supply costs |
|
|
159,557 |
|
|
|
90,840 |
|
|
|
315,461 |
|
|
|
181,731 |
|
Patient service equipment depreciation |
|
|
26,918 |
|
|
|
27,257 |
|
|
|
54,095 |
|
|
|
55,267 |
|
Home respiratory therapy services |
|
|
9,640 |
|
|
|
9,638 |
|
|
|
19,059 |
|
|
|
18,976 |
|
Nursing services |
|
|
8,513 |
|
|
|
2,262 |
|
|
|
17,566 |
|
|
|
4,366 |
|
Other |
|
|
4,832 |
|
|
|
4,434 |
|
|
|
8,549 |
|
|
|
8,708 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL COST OF NET REVENUES |
|
|
209,460 |
|
|
|
134,431 |
|
|
|
414,730 |
|
|
|
269,048 |
|
Provision for doubtful accounts |
|
|
5,271 |
|
|
|
11,093 |
|
|
|
15,952 |
|
|
|
20,791 |
|
Selling, distribution and administrative |
|
|
271,819 |
|
|
|
209,312 |
|
|
|
540,480 |
|
|
|
415,792 |
|
Amortization of intangible assets |
|
|
1,049 |
|
|
|
706 |
|
|
|
2,117 |
|
|
|
1,698 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL COSTS AND EXPENSES |
|
|
487,599 |
|
|
|
355,542 |
|
|
|
973,279 |
|
|
|
707,329 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING INCOME |
|
|
43,649 |
|
|
|
36,387 |
|
|
|
85,947 |
|
|
|
75,379 |
|
Interest expense |
|
|
5,556 |
|
|
|
5,722 |
|
|
|
13,872 |
|
|
|
12,042 |
|
Interest income and other |
|
|
(362 |
) |
|
|
(722 |
) |
|
|
(870 |
) |
|
|
(1,216 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME BEFORE TAXES |
|
|
38,455 |
|
|
|
31,387 |
|
|
|
72,945 |
|
|
|
64,553 |
|
Income tax expense |
|
|
15,300 |
|
|
|
12,136 |
|
|
|
29,018 |
|
|
|
24,452 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET INCOME |
|
$ |
23,155 |
|
|
$ |
19,251 |
|
|
$ |
43,927 |
|
|
$ |
40,101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per common share |
|
$ |
0.53 |
|
|
$ |
0.44 |
|
|
$ |
1.00 |
|
|
$ |
0.92 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per common share |
|
$ |
0.52 |
|
|
$ |
0.44 |
|
|
$ |
0.99 |
|
|
$ |
0.91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to unaudited condensed consolidated financial statements.
5
APRIA HEALTHCARE GROUP INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
June 30, |
|
(in thousands) |
|
2008 |
|
|
2007 |
|
|
|
|
|
|
|
(As Restated |
|
|
|
|
|
|
|
See Note 3) |
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net income |
|
$ |
43,927 |
|
|
$ |
40,101 |
|
Items included in net income not requiring cash: |
|
|
|
|
|
|
|
|
Provision for doubtful accounts |
|
|
15,952 |
|
|
|
20,791 |
|
Depreciation and amortization |
|
|
70,182 |
|
|
|
67,049 |
|
Amortization of deferred debt issuance costs |
|
|
889 |
|
|
|
889 |
|
Deferred income taxes |
|
|
33,863 |
|
|
|
5,607 |
|
Share-based compensation |
|
|
7,271 |
|
|
|
4,664 |
|
Loss (gain) on disposition of assets and other |
|
|
7,980 |
|
|
|
(138 |
) |
Excess tax benefits from share-based compensation |
|
|
(207 |
) |
|
|
(3,911 |
) |
Changes in operating assets and liabilities |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(16,110 |
) |
|
|
(21,001 |
) |
Inventories, net |
|
|
2,564 |
|
|
|
2,062 |
|
Prepaid expenses and other assets |
|
|
7,144 |
|
|
|
4,712 |
|
Accounts payable, exclusive of book-cash overdraft |
|
|
7,754 |
|
|
|
3,566 |
|
Accrued payroll and related taxes and benefits |
|
|
(5,323 |
) |
|
|
(815 |
) |
Income taxes payable |
|
|
(9,276 |
) |
|
|
7,970 |
|
Deferred revenue, net of related expenses |
|
|
960 |
|
|
|
1,291 |
|
Accrued expenses |
|
|
(10,142 |
) |
|
|
(1,227 |
) |
|
|
|
|
|
|
|
NET CASH PROVIDED BY OPERATING ACTIVITIES |
|
|
157,428 |
|
|
|
131,610 |
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Purchases of patient service equipment and property, equipment and improvements |
|
|
(96,301 |
) |
|
|
(55,811 |
) |
Proceeds from disposition of assets |
|
|
53 |
|
|
|
52 |
|
Cash paid for acquisitions |
|
|
(3,036 |
) |
|
|
|
|
|
|
|
|
|
|
|
NET CASH USED IN INVESTING ACTIVITIES |
|
|
(99,284 |
) |
|
|
(55,759 |
) |
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Proceeds from revolving credit facilities |
|
|
7,600 |
|
|
|
|
|
Payments on revolving credit facilities |
|
|
(67,600 |
) |
|
|
(80,000 |
) |
Payments on other long-term debt |
|
|
(2,293 |
) |
|
|
(2,145 |
) |
Change in book-cash overdraft included in accounts payable |
|
|
1,249 |
|
|
|
(345 |
) |
Capitalized debt issuance costs |
|
|
(3,079 |
) |
|
|
|
|
Excess tax benefits from share-based compensation |
|
|
207 |
|
|
|
3,911 |
|
Issuances of common stock |
|
|
382 |
|
|
|
16,554 |
|
|
|
|
|
|
|
|
NET CASH USED IN FINANCING ACTIVITIES |
|
|
(63,534 |
) |
|
|
(62,025 |
) |
|
|
|
|
|
|
|
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |
|
|
(5,390 |
) |
|
|
13,826 |
|
Cash and cash equivalents at beginning of period |
|
|
28,451 |
|
|
|
14,657 |
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
|
$ |
23,061 |
|
|
$ |
28,483 |
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES See Note 7 and Note 10 for cash paid for interest and income taxes,
respectively.
NON-CASH TRANSACTIONS See Note 8 for tax benefits from stock option exercises and non-cash
common stock and treasury stock transactions.
Purchases of patient service equipment and property, equipment and improvements exclude
purchases that remain unpaid at the end of the respective quarter. Such amounts are then included
in the following periods purchases when paid. Unpaid purchases were $13,181 and $10,994 at June
30, 2008 and December 31, 2007, respectively.
See notes to unaudited condensed consolidated financial statements.
6
APRIA HEALTHCARE GROUP INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation: The accompanying consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America. These
statements include the accounts of Apria Healthcare Group Inc. (Apria or the Company) and its
subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. The
three and six months ended June 30, 2007, respectively, have been restated, see Note 3 to these
unaudited condensed consolidated financial statements.
All adjustments, consisting of normal recurring accruals necessary for a fair presentation of
the results of operations for the interim periods presented, have been reflected herein. The
unaudited results of operations for interim periods are not necessarily indicative of the results
to be expected for the entire year. For further information, refer to the consolidated financial
statements and notes thereto included in the Companys Annual Report on Form 10-K/A for the fiscal
year ended December 31, 2007.
Use of Accounting Estimates: The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to
make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could materially differ from those estimates.
Revenue Recognition and Concentration of Credit Risk: Revenues are recognized under fee for
service/product arrangements through equipment the Company rents to patients, sales of equipment,
supplies, pharmaceuticals and other items the Company sells to patients and through capitation
payments received from third party payors for services and equipment the Company provides to the
patients of these payors. Revenue generated from equipment that the Company rents to patients is
recognized over the rental period, typically one month, and commences on delivery of the equipment
to the patients. Revenue related to sales of equipment, supplies and pharmaceuticals is recognized
on the date of delivery to the patients. Revenues derived from capitation arrangements were
approximately 8% of total net revenues for the three and six months ended June 30, 2008 and 11% for
the three and six months ended June 30, 2007, respectively. Capitation revenue is earned as a
result of entering into a contract with a third party to provide its members certain services
without regard to the actual services provided, therefore revenue is recognized in the period that
the beneficiaries are entitled to health care services. All revenues are recorded at amounts
estimated to be received under reimbursement arrangements with third-party payors, including
private insurers, prepaid health plans, Medicare and Medicaid. For the six months ended June 30,
2008 and 2007, revenues reimbursed under arrangements with Medicare and Medicaid were approximately
32% and 35%, respectively, as a percentage of total revenues. In both periods presented, no other
third-party payor group represented more than 9% of the Companys revenues. Rental and sale
revenues in the fee for service/product arrangement revenue line item were approximately
$188,296,000 or 38.6% and $299,782,000 or 61.4%, respectively, in the three months ended June 30,
2008, $179,847,000 or 51.3% and $170,772,000 or 48.7%, respectively, in the three months ended June
30, 2007, $373,507,000 or 38.4% and $599,927,000 or 61.6%, respectively, in the six months ended
June 30, 2008 and $360,838,000 or 51.5% and $339,276,000 or 48.5%, respectively in the six months
ended June 30, 2007.
Emerging Issues Task Force (EITF) Topic 00-21, Revenue Arrangements with Multiple
Deliverables, addresses the accounting for revenues in which multiple products and/or services are
delivered at different times under one arrangement with a customer, and provides guidance in
determining whether multiple deliverables should be considered as separate units of accounting. In
the Companys business, there are multiple products that are delivered to patients. These
arrangements involve equipment that is rented and related supplies that may be sold that cannot be
returned. In the Companys revenue recognition policy regarding arrangements with multiple
deliverables, revenue is recognized when each deliverable is provided to the patient. For example,
revenues from equipment rental supplies sales are recognized upon delivery of the products, as the
supplies sold are considered a separate unit of accounting.
Deferred Revenue and Deferred Expense: Rental of equipment to patients is accounted for under
Statement of Financial Accounting Standards (SFAS) No. 13, Accounting for Leases. Under SFAS
No. 13, a lessor is required to recognize rental income over the lease term. Rental of patient
equipment is billed on a monthly basis beginning on the date the equipment is delivered. Since
deliveries can occur on any day during a month, the amount of billings that apply to the next month
are deferred.
7
The accounting for the deferral of expenses by lessors is addressed by SFAS No. 91 Accounting
for Nonrefundable Fees and Costs Associated with Originating or Acquiring Loans and Initial Direct
Costs of Leases. Only the direct costs associated with the initial rental period are deferred in
accordance with SFAS No. 91.
Cash and Cash Equivalents: Cash is maintained with various financial institutions. These
financial institutions are located throughout the United States and the Companys cash management
practices limit exposure to any one institution. Book cash overdrafts, which are reported as a
component of accounts payable, were $15,477,000 and $14,228,000 at June 30, 2008 and December 31,
2007, respectively. Management considers all highly liquid instruments purchased with a maturity of
less than three months to be cash equivalents.
Accounts Receivable: Included in accounts receivable are earned but unbilled receivables of
$51,066,000 and $48,262,000 at June 30, 2008 and December 31, 2007, respectively. Delays ranging
from a day up to several weeks between the date of service and billing can occur due to delays in
obtaining certain required payor-specific documentation from internal and external sources. Earned
but unbilled receivables are aged from date of service and are considered in the analysis of
historical performance and collectibility.
Due to the nature of the industry and the reimbursement environment in which the Company
operates, certain estimates are required to record net revenues and accounts receivable at their
net realizable values. Inherent in these estimates is the risk that they will have to be revised or
updated as additional information becomes available. Specifically, the complexity of many
third-party billing arrangements and the uncertainty of reimbursement amounts for certain services
from certain payors may result in adjustments to amounts originally recorded. Such adjustments are
typically identified and recorded at the point of cash application, claim denial or account review.
Management performs periodic analyses to evaluate accounts receivable balances to ensure that
recorded amounts reflect estimated net realizable value. Specifically, management considers
historical realization data, accounts receivable aging trends, other operating trends, the extent
of contracted business and business combinations. Also considered are relevant business conditions
such as governmental and managed care payor claims processing procedures and system changes.
Additionally, focused reviews of certain large and/or problematic payors are performed. Due to
continuing changes in the healthcare industry and third-party reimbursement, it is possible that
managements estimates could change in the near term, which could have an impact on operations and
cash flows.
Accounts receivable are reduced by an allowance for doubtful accounts which provides for those
accounts from which payment is not expected to be received, although services were provided and
revenue was earned. Upon determination that an account is uncollectible, it is written-off and
charged to the allowance.
Beginning
with the quarter ended June 30, 2008, the Company corrected the
classification of certain obligations to its payors reclassifying the
obligation from a reduction to accounts receivable to other accrued
liabilities. The correction was
not material to the condensed consolidated balance sheet as of
June 30, 2008. No correction has been made to any prior periods.
Capitalized Software: Included in property, equipment and improvements are costs related to
internally developed and purchased software that are capitalized and amortized over periods that
the assets are expected to provide benefit and are accounted for under Statement of Position No.
98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use.
Capitalized costs include direct costs of materials and services incurred in developing or
obtaining internal-use software and payroll and benefit costs for employees directly involved in
the development of internal-use software. Additions to capitalized software, including capitalized
interest, totaled $8,779,000 and $14,697,000 for the three and six months ended June 30, 2008,
respectively.
Home Respiratory Therapy Expenses: Home respiratory therapy expenses presented within cost of
net revenues are comprised primarily of employee salary and benefit costs or contract fees paid to
respiratory therapists and other related professionals who are deployed to service a patient. Home
respiratory therapy personnel are also engaged in a number of administrative and marketing tasks,
and accordingly, these costs are classified within selling, distribution and administrative
expenses and amounted to $5,263,000 and $4,873,000 for the three month periods ended June 30, 2008
and 2007, respectively, and $10,787,000 and $9,729,000 for the six month periods ended June 30,
2008 and 2007, respectively.
Distribution Expenses: Distribution expenses are included in selling, distribution and
administrative expenses and totaled $48,572,000 and $43,880,000 for the three months ended June 30,
2008 and 2007, respectively, and $96,481,000 and $87,597,000 for the six month periods ended June
30, 2008 and 2007, respectively. Such expenses represent the cost incurred to coordinate and
deliver products and services to patients. Included in distribution expenses are leasing,
maintenance, licensing and fuel costs for the vehicle fleet; salaries and other costs related to
drivers and dispatch personnel; and amounts paid to courier and other outside shipping vendors.
Such expenses fall within the definition of shipping and handling costs as discussed in EITF No.
00-10 Accounting for Shipping and Handling Fees and Costs, which permits such expenses to be
classified within selling and administrative expenses.
8
Sales
and Certain Other Taxes: In its consolidated financial statements, Apria accounts for
taxes imposed on revenue-producing transactions by government authorities on a net basis, and
accordingly, excludes such taxes from net revenues. Such taxes include, but are not limited to
sales, use, privilege and excise taxes.
Other:
Beginning
with the quarter ended June 30, 2008, the Company corrected the classification of
losses on disposal of patient services equipment from a
reduction in its purchases of patient service equipment in investing
activities in the condensed consolidated statement of cash flows to a loss on disposal
in the cash provided by operating activities in the condensed consolidated statement
of cash flows. The correction was not material to the condensed
consolidated statement of cash flows as of June 30, 2008. No correction has been made to any prior periods.
NOTE 2 RECENT DEVELOPMENTS
Merger Agreement. On June 18, 2008, the Company entered into an Agreement and Plan of Merger
(the Merger Agreement) with Sky Acquisition LLC, a Delaware limited liability company (Buyer)
and Sky Merger Sub Corporation, a Delaware corporation and wholly-owned subsidiary of Buyer
(Merger Sub). Buyer is controlled by a private investment fund affiliated with The Blackstone
Group (Blackstone), which is providing a portion of the funding for the transaction.
The Merger Agreement provides that, upon the terms and subject to the conditions set forth in
the Merger Agreement, Merger Sub will merge with and into the Company (the Merger) with the
Company continuing as the surviving corporation and a wholly-owned subsidiary of Buyer. As of the
effective time of the Merger, each issued and outstanding share of common stock of the Company will
be cancelled and converted into the right to receive $21.00 in cash, without interest and less
applicable withholding taxes (the Merger Consideration). Buyer and Merger Sub have obtained
equity and debt financing commitments for the transactions contemplated by the Merger Agreement,
the aggregate proceeds of which will be sufficient for Buyer to pay the aggregate Merger
Consideration and all related fees and expenses. Debt financing commitments of $1.15 billion have
been provided by a syndicate comprised of Bank of America, Wachovia Bank, and Barclays Capital.
Consummation of the Merger is not subject to a financing condition, but is subject to various other
conditions, including approval of the Merger Agreement by the Companys stockholders, expiration or
termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 as amended (the HSR Act), accuracy of the representations and warranties of the Company, and
other customary closing conditions. On July 8, 2008, the Company received notice that the federal
antitrust authorities have granted early termination of the waiting period under the HSR Act. The
parties expect to close the transaction later in 2008.
The Company has made various representations and warranties and agreed to certain covenants in
the Merger Agreement, including covenants relating to the Companys conduct of its business between
the date of the Merger Agreement and the closing of the Merger, governmental filings and approvals,
public disclosures and other matters.
The Merger Agreement contains certain termination rights for both the Company and Buyer. The
Merger Agreement provides that, upon termination under specified circumstances, the Company would
be required to pay Buyer a termination fee. The Merger Agreement further provides that, upon
termination under other specified circumstances, Buyer would be required to pay the Company a
reverse termination fee. The reverse termination fee potentially payable by Buyer is guaranteed by
an investment fund affiliated with Blackstone, in a separate limited guarantee.
Liquidity Credit Facility. On June 18, 2008, the Company also entered into a $280 million
credit facility pursuant to a Credit Agreement with Banc of America Bridge LLC, Barclays Capital
PLC and Wachovia Capital Markets, LLC (the Credit
Agreement). On September 2, 2008 proceeds of the new credit facility
were used to fund repurchases of the Companys 3 3/8% Convertible Senior Notes due
2033 and will be used to pay certain tax liabilities related thereto. The loans under the credit facility bear
interest at a rate of eleven per cent (11%) per year with a maturity date of March 1, 2009. In
addition, the Company paid usual and customary bank fees in connection with entering into the
Credit Agreement. The Credit Agreement includes restrictions on the Company regarding additional
indebtedness, business operations, liens, transfers and sales of assets, and transactions with
affiliates. The Credit Agreement also contains customary events of default which would permit the
lenders to accelerate payments under the Credit Agreement if not cured within applicable grace
periods, including the failure to make timely payments under the Credit Agreement and the failure
to follow certain covenants. As of June 30, 2008, the Company
was in compliance with all covenants, but, due to the non-timely filing of
the Companys quarterly report on Form 10-Q for the period
ended June 30, 2008,
the Company would have been in default of the reporting covenants
under the Credit Agreement on August 15, 2008. However, the
Companys lenders executed a waiver on August 14, 2008, which extended the filing requirement
from 45 days to 90 days following the end of the quarter.
Upon the
filing of this quarterly report on Form 10-Q for the
period ended June 30, 2008, the Company will have remedied the
non-compliance with reporting requirements under its Credit
Agreement. See Note 7 and Note 13.
Convertible
Senior Notes. On September 2, 2008, the Company repurchased
$249.8 million in aggregate principal of its 3 3/8% Convertible Senior Notes
Due 2033 (the “senior notes”) representing approximately 99.91% of
the outstanding principal amount. $0.2 million in aggregate principal amount of the
senior notes remains outstanding.
On August 26,
2008, Apria received a notice of default from the trustee under the indenture
governing the senior notes regarding Apria’s failure to deliver its
Quarterly Report on Form 10-Q for the period ended June 30, 2008 within
the specified time period. Pursuant to the indenture, failure by Apria to
comply with such reporting requirements will become an event of default if not
remedied within 60 days after the date on which written notice of such
failure, requiring Apria to remedy the same, is given to Apria by the trustee,
and the senior notes, together with accrued and unpaid interest thereon, shall
become due and payable immediately upon notice to the Company from the Trustee
or the holders of not less than 25% in aggregate principal amount of the senior
notes then outstanding.
Upon the
filing of this quarterly report on Form 10-Q for the
period ended June 30, 2008,
the Company will have remedied the default under its senior notes.
NOTE 3 RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS
Historically, the Company accounted for deferred revenues and deferred expenses related to
equipment it rents to patients under a reimbursement contract method. These deferred amounts were
included in its consolidated financial statements for the year ended December 31, 2006, on which
the Companys independent registered public accountants, Deloitte & Touche LLP, issued an
unqualified opinion. In the course of the Companys fourth quarter 2007 review of the Companys
accounting for deferred revenue and deferred expenses it was identified that the Company had
incorrectly deferred revenue related to all of the Companys capitated contracts (in the fee for
service/product arrangements line item) and that the Company incorrectly deferred certain indirect
and overhead expenses. The Company concluded that the rental of such equipment should be accounted
for under SFAS No. 13, Accounting for Leases. Under SFAS No. 13 lessors are required to recognize
rental income over the lease term. The Company bills for the rental of patient equipment on a
monthly basis beginning on the date the equipment is delivered. Since deliveries can occur on any
day during a month, revenue must be deferred for the amount of billings that apply to the next
month.
9
The accounting for the deferral of expenses by lessors is addressed by SFAS No. 91 Accounting
for Nonrefundable Fees and Costs Associated with Originating or Acquiring Loans and Initial Direct
Costs of Leases. Under SFAS No. 91 only the direct costs associated with leases are to be
deferred. The Company has re-evaluated the amount of costs to be deferred and now will be deferring
only the direct costs associated with the initial rental period under SFAS No. 91 and have adjusted
its financial statements accordingly.
On December 31, 2007, the Companys management concluded to restate its previously issued
financial statements because of reporting errors solely relating to its accounting for deferred
revenue and deferred expenses related to equipment it rents to patients. Accordingly, the Company
restated its condensed consolidated statements of income for the three and six months ended June
30, 2007 and its condensed consolidated statement of cash flows for the six months ended June 30, 2007. The impact of the restatement
decreased net income for the three months ended June 30, 2007 by $1.6 million or 7.6%, and
increased net income for the six months ended June 30, 2007 by $0.1 million or 0.3%.
The following tables show the impact of the restatement.
CONDENSED CONSOLIDATED STATEMENT OF INCOME ITEMS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2007 |
|
|
|
(As Previously |
|
|
|
|
|
|
(As |
|
(in thousands, except per share data) |
|
Reported) |
|
|
(Adjustments) |
|
|
Restated) |
|
Fee for service/product arrangements |
|
$ |
352,734 |
|
|
$ |
(2,115 |
) |
|
$ |
350,619 |
|
Total net revenues |
|
|
394,044 |
|
|
|
(2,115 |
) |
|
|
391,929 |
|
Product and supply costs |
|
|
90,894 |
|
|
|
(54 |
) |
|
|
90,840 |
|
Total cost of net revenues |
|
|
134,485 |
|
|
|
(54 |
) |
|
|
134,431 |
|
Selling, distribution and administrative expenses |
|
|
209,406 |
|
|
|
(94 |
) |
|
|
209,312 |
|
Total costs and expenses |
|
|
355,690 |
|
|
|
(148 |
) |
|
|
355,542 |
|
Operating income |
|
|
38,354 |
|
|
|
(1,967 |
) |
|
|
36,387 |
|
Income before taxes |
|
|
33,354 |
|
|
|
(1,967 |
) |
|
|
31,387 |
|
Income tax expense |
|
|
12,525 |
|
|
|
(389 |
) |
|
|
12,136 |
|
Net income |
|
|
20,829 |
|
|
|
(1,578 |
) |
|
|
19,251 |
|
Basic net income per common share |
|
|
0.48 |
|
|
|
|
|
|
|
0.44 |
|
Diluted net income per common share |
|
$ |
0.47 |
|
|
|
|
|
|
$ |
0.44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2007 |
|
|
|
(As Previously |
|
|
|
|
|
|
(As |
|
(in thousands, except per share data) |
|
Reported) |
|
|
(Adjustments) |
|
|
Restated) |
|
Fee for service/product arrangements |
|
$ |
700,740 |
|
|
$ |
(626 |
) |
|
$ |
700,114 |
|
Total net revenues |
|
|
783,334 |
|
|
|
(626 |
) |
|
|
782,708 |
|
Product and supply costs |
|
|
181,964 |
|
|
|
(233 |
) |
|
|
181,731 |
|
Total cost of net revenues |
|
|
269,281 |
|
|
|
(233 |
) |
|
|
269,048 |
|
Selling, distribution and administrative expenses |
|
|
415,985 |
|
|
|
(193 |
) |
|
|
415,792 |
|
Total costs and expenses |
|
|
707,755 |
|
|
|
(426 |
) |
|
|
707,329 |
|
Operating income |
|
|
75,579 |
|
|
|
(200 |
) |
|
|
75,379 |
|
Income before taxes |
|
|
64,753 |
|
|
|
(200 |
) |
|
|
64,553 |
|
Income tax expense |
|
|
24,780 |
|
|
|
(328 |
) |
|
|
24,452 |
|
Net income |
|
|
39,973 |
|
|
|
128 |
|
|
|
40,101 |
|
Basic net income per common share |
|
|
0.92 |
|
|
|
|
|
|
|
0.92 |
|
Diluted net income per common share |
|
$ |
0.91 |
|
|
|
|
|
|
$ |
0.91 |
|
10
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS ITEMS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2007 |
|
|
|
(As Previously |
|
|
|
|
|
|
(As |
|
(in thousands) |
|
Reported) |
|
|
(Adjustments) |
|
|
Restated) |
|
Net income |
|
$ |
39,973 |
|
|
$ |
128 |
|
|
$ |
40,101 |
|
Deferred income taxes |
|
|
5,935 |
|
|
|
(328 |
) |
|
|
5,607 |
|
Deferred revenue, net of deferred expenses |
|
$ |
1,091 |
|
|
$ |
200 |
|
|
$ |
1,291 |
|
NOTE 4 RECENT ACCOUNTING PRONOUNCEMENTS
In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS No. 157,
Fair Value Measurements, which defines fair value, establishes a framework for measuring fair
value in generally accepted accounting principles, and expands disclosures about fair value
measurements. The statement is effective for financial statements issued for fiscal years beginning
after November 15, 2007, and interim periods within those fiscal years. On January 1, 2008, the
Company adopted SFAS No. 157.
In February 2008, the FASB issued FASB Staff Position (FSP) No. FAS 157-1, Application of
FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address
Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13
(FSP FAS 157-1). FSP FAS 157-1 provides a scope exception from SFAS No. 157 for the evaluation
criteria on lease classification and capital lease measurement under SFAS No. 13, Accounting for
Leases and other related accounting pronouncements. Accordingly, the Company did not apply the
provisions of SFAS No. 157 in determining the classification of and accounting for leases and the
adoption of FSP FAS 157-1 did not have an impact on the Companys condensed consolidated financial
statements.
FSP No. FAS 157-2 (FSP 157-2), Effective Date of FASB Statement No. 157 was issued in
February 2008. FSP 157-2 delays the effective date of SFAS No. 157, for nonfinancial assets and
nonfinancial liabilities, except for items that are recognized or disclosed at fair value at least
once a year, to fiscal years beginning after November 15, 2008, and for interim periods within
those fiscal years. The Company is currently assessing the impact of SFAS No. 157 for non-financial
assets and non-financial liabilities on its consolidated statements of financial position and
results of operations.
Fair Value Hierarchy. SFAS No. 157 defines the inputs used to measure fair value into the
following hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market
data.
Level 3: Unobservable inputs reflecting the reporting entitys own assumptions.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets
and Financial Liabilities. SFAS No. 159 expands opportunities to use fair value measurement in
financial reporting and permits entities to choose to measure many financial instruments and
certain other items at fair value. SFAS No. 159 is effective for fiscal years beginning after
November 15, 2007. The Company adopted SFAS No. 159 on January 1, 2008. The Company evaluated SFAS
No. 159 and did not elect the fair value accounting option for any of its eligible assets and
liabilities; therefore, the adoption of SFAS No. 159 had no impact on its financial statements.
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. SFAS No. 141(R)
replaces SFAS No. 141, Business Combinations. SFAS No. 141(R) retains the fundamental
requirements in SFAS No. 141 that the acquisition method of accounting be used for all business
combinations and for an acquirer to be identified for each business combination. SFAS No. 141(R)
amends the recognition provisions for assets and liabilities acquired in a business combination,
including those arising from contractual and noncontractual contingencies. SFAS No. 141(R) also
amends the recognition criteria for contingent consideration. In addition, under SFAS No. 141(R),
changes in an acquired entitys deferred tax assets and uncertain tax positions after the
measurement period will impact income tax expense. SFAS No. 141(R) is effective for fiscal years
beginning on or after December 15, 2008. Early adoption is not permitted.
11
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated
Financial StatementsAn Amendment of ARB No. 51. SFAS No. 160 establishes new accounting and
reporting standards for the non-controlling interest in a subsidiary and for the deconsolidation of
a subsidiary. SFAS No. 160 is effective for fiscal years beginning on or after December 15, 2008.
Management does not currently expect the adoption of SFAS No. 160 to have a material impact on the
Companys consolidated financial statements.
In April 2008, FASB issued FSP No. 142-3 (FSP 142-3), Determination of the Useful Life of
Intangible Assets, which amends the factors that must be considered in developing renewal or
extension assumptions used to determine the useful life over which to amortize the cost of a
recognized intangible asset under SFAS No. 142, Goodwill and Other Intangible Assets. FSP 142-3
requires an entity to consider its own assumptions about renewal or extension of the term of the
arrangement, consistent with its expected use of the asset. FSP 142-3 also requires the disclosure
of the weighted-average period prior to the next renewal or extension for each major intangible
asset class, the accounting policy for the treatment of costs incurred to renew or extend the term
of recognized intangible assets and for intangible assets renewed or extended during the period, if
renewal or extension costs are capitalized, the costs incurred to renew or extend the asset and the
weighted-average period prior to the next renewal or extension for each major intangible asset
class. FSP 142-3 is effective for financial statements for fiscal years beginning after December
15, 2008. The Company is currently evaluating the impact of adopting FSP 142-3 on its consolidated
financial statements.
In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting
Principles. SFAS No. 162 identifies the sources of accounting principles and the framework for
selecting principles to be used in the preparation of financial statements of nongovernmental
entities that are presented in conformity with generally accepted accounting principles in the
United States. This statement shall be effective 60 days following the SECs approval of the
Public Company Accounting Oversight Boards amendments to AU section 411, The Meaning of Present
Fairly in Conformity with Generally Accepted Accounting Principles. The Company is currently
evaluating the impact of SFAS No. 162, but does not expect the adoption of this pronouncement will
have a material impact on its financial position, results of operations or cash flows.
NOTE 5 BUSINESS COMBINATIONS
Apria periodically makes acquisitions of complementary businesses in specific geographic
markets. The results of operations of the acquired companies are included in the accompanying
condensed consolidated income statements from the dates of acquisition. No acquisitions were made
during the six months ended June 30, 2008 and 2007. Cash paid for acquisitions, which includes
amounts deferred from prior periods, totaled $3.0 million for the six months ended June 30, 2008.
NOTE 6 GOODWILL AND INTANGIBLE ASSETS
Business combinations are accounted for in accordance with SFAS No. 141, Business
Combinations, which requires that the purchase method of accounting be applied to all business
combinations and addresses the criteria for initial recognition of intangible assets and goodwill.
Additionally, in accordance with SFAS No. 142, Goodwill and Other Intangible Assets, goodwill and
other intangible assets with indefinite lives are not amortized but are tested for impairment
annually, or more frequently if circumstances indicate the possibility of impairment. If the
carrying value of goodwill or an intangible asset exceeds its fair value, an impairment loss shall
be recognized.
The intangible assets on the Companys books consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2008 |
|
|
December 31, 2007 |
|
|
|
Average |
|
|
Gross |
|
|
|
|
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
Net |
|
|
|
Life in |
|
|
Carrying |
|
|
Accumulated |
|
|
Net Book |
|
|
Carrying |
|
|
Accumulated |
|
|
Book |
|
(dollars in thousands) |
|
Years |
|
|
Amount |
|
|
Amortization |
|
|
Value |
|
|
Amount |
|
|
Amortization |
|
|
Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets subject to amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Covenants not to compete |
|
|
5.0 |
|
|
$ |
10,618 |
|
|
$ |
(8,084 |
) |
|
$ |
2,534 |
|
|
$ |
11,380 |
|
|
$ |
(7,744 |
) |
|
$ |
3,636 |
|
Patient referral sources |
|
|
20.0 |
|
|
|
34,300 |
|
|
|
(1,000 |
) |
|
|
33,300 |
|
|
|
34,300 |
|
|
|
(143 |
) |
|
|
34,157 |
|
Favorable leases |
|
|
2.4 |
|
|
|
628 |
|
|
|
(179 |
) |
|
|
449 |
|
|
|
584 |
|
|
|
(20 |
) |
|
|
564 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
9.1 |
|
|
|
45,546 |
|
|
|
(9,263 |
) |
|
|
36,283 |
|
|
|
46,264 |
|
|
|
(7,907 |
) |
|
|
38,357 |
|
Intangible assets not subject to amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade names |
|
|
|
|
|
|
69,400 |
|
|
|
|
|
|
|
69,400 |
|
|
|
69,400 |
|
|
|
|
|
|
|
69,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
9.1 |
|
|
$ |
114,946 |
|
|
$ |
(9,263 |
) |
|
$ |
105,683 |
|
|
$ |
115,664 |
|
|
$ |
(7,907 |
) |
|
$ |
107,757 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12
Amortization expense amounted to $1,049,000 and $706,000 for the three months ended June 30,
2008 and 2007, respectively. Amortization expense amounted to $2,117,000 and $1,698,000 for the six
months ended June 30, 2008 and 2007. Estimated amortization expense for each of the fiscal years
ending December 31 is presented below:
|
|
|
|
|
Year Ending December 31, |
|
(in thousands) |
|
2008 |
|
$ |
7,194 |
|
2009 |
|
|
4,425 |
|
2010 |
|
|
2,611 |
|
2011 |
|
|
2,129 |
|
2012 |
|
|
1,992 |
|
NOTE 7 LONG-TERM DEBT
Revolving Credit Facility: At June 30, 2008, borrowings under the Companys revolving credit
facility were $364,000,000, outstanding letters of credit totaled $7,849,000, credit available
under the revolving credit facility was $128,151,000, and Apria was in compliance with all
covenants required by the Fourth Amended and Restated Credit Agreement with certain lenders, dated
November 23, 2004, as amended (the 2004 Credit Agreement). The effective interest rate at June
30, 2008, after consideration of the effect of the swap agreement described below, was 3.2%.
Convertible Senior Notes:
In August 2003, convertible senior notes in the aggregate principal amount of $250,000,000
were issued under an indenture with U.S. Bank National Association. The notes were issued in a
private placement at an issue price of $1,000 per note (100% of the principal amount at maturity)
and were subsequently registered with the Securities and Exchange
Commission. At June 30, 2008, the fair value of the $250,000,000 in the
Companys outstanding convertible senior notes was $249,300,000, as determined by reference to
quoted market prices. On September 2, 2008, the Company repurchased
$249,772,000 in aggregate principal of the senior notes, representing
approximately 99.91% of the outstanding principal amount.
$228,000 in principal amount of the senior notes remains outstanding.
On August 26,
2008, Apria received a notice of default from the trustee under the indenture
governing the senior notes regarding Apria’s failure to deliver its
Quarterly Report on Form 10-Q for the period ended June 30, 2008 within
the specified time period. Pursuant to the indenture, failure by Apria to
comply with such reporting requirements will become an event of default if not
remedied within 60 days after the date on which written notice of such
failure, requiring Apria to remedy the same, is given to Apria by the trustee,
and the remaining senior notes, together with accrued and unpaid interest thereon, shall
become due and payable immediately upon notice to the Company from the Trustee
or the holders of not less than 25% in aggregate principal amount of the senior
notes then outstanding. Upon the filing of this
quarterly report on Form 10-Q for the period ended
June 30, 2008, the
Company will have remedied the default under its senior notes.
Liquidity Credit Facility: On June 18, 2008, the Company entered into a $280 million credit
facility pursuant to the Credit Agreement. On September 2, 2008
proceeds of the new credit facility were used to fund repurchases of
the senior notes and will
be used to pay certain
tax liabilities related thereto. The loans under the credit facility bear interest at a rate of
eleven per cent (11%) per year with a maturity date of March 1, 2009. In addition, the Company paid
usual and customary bank fees in connection with entering into the Credit Agreement. The Credit
Agreement includes restrictions on the Company regarding additional indebtedness, business
operations, liens, transfers and sales of assets, and transactions with affiliates. The Credit
Agreement also contains customary events of default which would permit the lenders to accelerate
payments under the Credit Agreement if not cured within applicable grace periods, including the
failure to make timely payments under the Credit Agreement and the failure to follow certain
covenants. As of June 30, 2008, the Company was in compliance
with all covenants, but, due to the non-timely filing of the
Companys quarterly report on Form 10-Q, for the period
ended June 30, 2008, the Company would have been in default of the reporting covenants
under the Credit Agreement on August 15, 2008. However, the Companys
lenders executed a waiver on August 14,
2008, which extended the filing requirement from 45 days to 90 days
following the end of the quarter. Upon the
filing of this quarterly report on Form 10-Q for the
period ended June 30, 2008, the Company will have remedied the
non-compliance with reporting requirements under its Credit
Agreement.
Hedging Activities: Apria utilizes interest rate swap agreements to moderate its exposure to
interest rate fluctuations on its underlying variable rate long-term debt. Apria does not use
derivative financial instruments for trading or other speculative purposes. At June 30, 2008, Apria
had one interest rate swap agreement in effect which will expire in January 2009, with a notional
amount of $25,000,000 and a fixed rate of 4.44%.
13
The swap agreement is accounted for under SFAS No. 133, Accounting for Derivative Instruments
and Hedging Activities. The difference between the interest received and interest paid is
reflected as an adjustment to interest expense. Apria received a net settlement amount of $18,000
and $58,000 related to the three-month period ended June 30, 2008 and 2007, respectively, and
$69,000 and $117,000 for the six months ended June 30, 2008 and 2007, respectively. The aggregate
fair value of the swap agreement was a liability of $198,000 and $105,000 at June 30, 2008 and
December 31, 2007, respectively, and is reflected in the accompanying condensed consolidated
balance sheets in other accrued liabilities. The Companys interest rate swap agreement is valued
using observable market based inputs and therefore is classified within Level 2 of the fair value
hierarchy. Unrealized gains and losses on the fair value of the swap agreement are reflected in net
income, as the transaction does not qualify for hedge accounting. Aprias exposure to credit loss
under the swap agreement is limited to the interest rate spread in the event of counterparty
nonperformance. Apria does not anticipate losses due to counterparty nonperformance as its
counterparties to the swap agreement are nationally recognized financial institutions with strong
credit ratings.
On August 30, 2007, Apria acquired information systems software totaling $5,800,000 under an
installment payment agreement, of which $3,600,000 is considered as
long-term debt as of June 30, 2008.
Interest paid on debt totaled $4,172,000 and $2,899,000 for the three months ended June 30,
2008 and 2007, respectively, and $14,045,000 and $10,685,000 for the six months ended June 30, 2008
and 2007, respectively.
NOTE 8 STOCKHOLDERS EQUITY
For the six months ended June 30, 2008, changes to stockholders equity were comprised of the
following amounts:
|
|
|
|
|
Net income |
|
$ |
43,927 |
|
Issuances of common stock (including non-cash issuances) |
|
|
480 |
|
Excess tax benefits from share-based compensation |
|
|
207 |
|
Tax shortfalls on share-based compensation |
|
|
(631 |
) |
Restricted stock retained in treasury upon vesting |
|
|
(1,264 |
) |
Share-based compensation |
|
|
7,271 |
|
Other comprehensive loss, net of taxes |
|
|
(60 |
) |
|
|
|
|
|
|
$ |
49,930 |
|
|
|
|
|
Net income and total comprehensive income differ by other comprehensive loss, net of taxes.
Such loss represents the amortization of a balance in accumulated other comprehensive income that
was previously recorded in connection with certain interest rate swap agreements. For the three
months ended June 30, 2008 and 2007, total comprehensive income was $22,579,000 and $19,216,000 and
for the six months ended June 30, 2008 and 2007, $43,321,000 and $40,021,000, respectively.
Common stock valued at $98,000 was issued during the six months ended June 30, 2008 in a
non-cash transaction. This transaction was related to the exercise of a restricted stock purchase
right for an executive.
NOTE 9 SHARE-BASED COMPENSATION
For the three and six months ended June 30, 2008, the Company recorded share-based
compensation expense of $4,121,000 and $7,271,000. Share-based compensation expense was $3,228,000
and $4,664,000, for the corresponding three and six-month periods in 2007. All such compensation is
reflected in the accompanying condensed consolidated income statement within the selling,
distribution and administrative expense line item. The related awards were granted to executive and
certain management personnel or members of the Companys Board of Directors and therefore no
portion of the share-based compensation has been classified within cost of net revenues.
Share-based compensation expense recognized in the periods presented is based on awards ultimately
expected to vest; therefore, it has been reduced for estimated forfeitures.
For the six months ended June 30, 2008 and 2007, cash received from the exercise of
share-based awards totaled $382,000 and $16,554,000, respectively.
14
The Company estimates the fair value of stock options using the Black-Scholes valuation model.
Key input assumptions used to estimate the fair value of stock options include the exercise price
of the award, the expected option term, the expected volatility of the Companys stock over the
options expected term, the risk-free interest rate over the options term, and the Companys
expected annual dividend yield. Aprias management believes that the valuation technique and the
approach utilized to develop the underlying assumptions are appropriate in calculating the fair
values of the Companys stock options granted in the three and six month periods ended June 30,
2008 and June 30, 2007, respectively. Estimates of fair value are not intended to predict actual
future events or the value ultimately realized by persons who receive equity awards. The key input
assumptions that were utilized in the valuation of the stock options granted during the six months
ended June 30, 2008 and 2007, are summarized in the table below.
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
|
2008 |
|
|
2007 |
|
Expected option term(1) |
|
6.2 years |
|
|
4.6 years |
|
Expected volatility(2) |
|
|
37.3 |
% |
|
|
29.9 |
% |
Risk-free interest rate(3) |
|
|
3.1 |
% |
|
|
4.6 |
% |
Expected annual dividend yield |
|
|
0 |
% |
|
|
0 |
% |
|
|
|
(1) |
|
The expected option term is based on historical exercise and post-vesting termination
patterns. |
|
(2) |
|
The expected volatility represents a combination of historical stock price volatility and
implied volatility from publicly-traded options on Aprias common stock. |
|
(3) |
|
The risk-free interest rate is based on the implied yield on a U.S. Treasury zero coupon
issue with a remaining term equal to the expected term of the option. |
Stock Options: Aprias incentive plan provides for the granting of stock options to employees
and non-employee directors. In the past, such grants to employees have included both non-qualified
and incentive stock options; however, in May 2007 the Compensation Committee of the Companys Board
of Directors determined to grant only non-qualified options in the future. The exercise price of an
option is established at the fair market value of a share of Apria common stock on the date of
grant. Vesting of stock options is time-based and is generally over a three-year period.
The following table summarizes the activity for stock options for the six months ended June
30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Remaining |
|
|
Aggregate |
|
|
|
|
|
|
|
Weighted-Average |
|
|
Contractual Term |
|
|
Intrinsic |
|
|
|
Options |
|
|
Exercise Price |
|
|
(in Years) |
|
|
Value |
|
Outstanding at January 1, 2008 |
|
|
3,733,383 |
|
|
$ |
26.60 |
|
|
|
|
|
|
|
|
|
Granted |
|
|
15,000 |
|
|
$ |
21.02 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(53,166 |
) |
|
$ |
7.20 |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
(113,838 |
) |
|
$ |
29.89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2008 |
|
|
3,581,379 |
|
|
$ |
26.76 |
|
|
|
5.87 |
|
|
$ |
465,206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested or expected to vest as of June 30, 2008 |
|
|
3,396,051 |
|
|
$ |
26.75 |
|
|
|
5.73 |
|
|
$ |
464,455 |
|
Exercisable at June 30, 2008 |
|
|
2,790,393 |
|
|
$ |
26.69 |
|
|
|
5.12 |
|
|
$ |
462,006 |
|
The weighted-average fair value of stock options granted during the six months ended June 30,
2008 and 2007 was $6.55 and $10.60, respectively. There were 646,830 stock options granted in the
six-month period ended June 30, 2007. The total intrinsic value of options exercised was $533,000
and $9,371,000 for the six months ended June 30, 2008 and 2007, respectively.
As of June 30, 2008, total unrecognized stock-based compensation cost related to unvested
stock options was $4,771,000, which is expected to be expensed over a weighted-average period of
1.50 years.
Restricted Stock Purchase Rights: In 2003 and 2004, Apria granted restricted stock purchase
rights to certain members of executive management. The awards represented the right to purchase a
certain number of shares of Apria common stock at a future date at a specified exercise price. The
exercise price was established at 25% of the fair market value of a share of Apria common stock on
the date of grant. Such awards generally require that certain performance conditions and/or service
conditions be met before the awards will vest.
15
The following table summarizes the activity for restricted stock purchase rights for the six
months ended June 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted |
|
|
|
|
|
|
Weighted-Average |
|
|
|
|
|
|
Stock |
|
|
|
|
|
|
Remaining |
|
|
Aggregate |
|
|
|
Purchase |
|
|
Weighted-Average |
|
|
Contractual Term |
|
|
Intrinsic |
|
|
|
Rights |
|
|
Exercise Price |
|
|
(in Years) |
|
|
Value |
|
Outstanding at January 1, 2008 |
|
|
277,000 |
|
|
$ |
6.82 |
|
|
|
|
|
|
|
|
|
Granted |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(15,000 |
) |
|
$ |
6.46 |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2008 |
|
|
262,000 |
|
|
$ |
6.84 |
|
|
|
5.29 |
|
|
$ |
3,288,480 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested or expected to vest as of June 30, 2008 |
|
|
208,055 |
|
|
$ |
6.82 |
|
|
|
5.28 |
|
|
$ |
2,616,074 |
|
Exercisable at June 30, 2008 |
|
|
8,000 |
|
|
$ |
6.46 |
|
|
|
5.12 |
|
|
$ |
103,440 |
|
The total intrinsic value of restricted stock purchase rights exercised was $193,950 and
$534,000 for the six months ended June 30, 2008 and 2007, respectively. No such awards were granted
during these two periods.
As of June 30, 2008, total unrecognized stock-based compensation cost related to unvested
restricted stock purchase rights was $1,580,000, which is expected to be expensed over a
weighted-average period of 1.84 years.
Stock Appreciation Rights: On February 29, 2008, Apria granted stock appreciation rights to
certain members of executive management under the 2003 Performance Incentive Plan. The awards
represent the right to receive a payment in stock, equal to the excess of the fair market value of
a specified number of shares of Apria common stock on the date the stock appreciation right is
exercised over the fair market value of a share of Apria common stock on the date the stock
appreciation right was granted (the base price). Generally, the base price may not be less than
the per share fair market value on the date of grant. Vesting of stock appreciation rights is
time-based and is over a four-year period.
The following table summarizes the activity for stock appreciation rights for the six months
ended June 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average |
|
|
|
|
|
|
Stock |
|
|
|
|
|
|
Remaining |
|
|
Aggregate |
|
|
|
Appreciation |
|
|
Weighted-Average |
|
|
Contractual Term |
|
|
Intrinsic |
|
|
|
Rights |
|
|
Exercise Price |
|
|
(in Years) |
|
|
Value |
|
Outstanding at January 1, 2008 |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
Granted |
|
|
773,850 |
|
|
$ |
20.51 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
(5,960 |
) |
|
$ |
21.71 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2008 |
|
|
767,890 |
|
|
$ |
20.50 |
|
|
|
9.71 |
|
|
$ |
220,052 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested or expected to vest as of June 30, 2008 |
|
|
591,106 |
|
|
$ |
20.50 |
|
|
|
9.71 |
|
|
$ |
169,380 |
|
Exercisable at
June 30, 2008 |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
$ |
|
|
The weighted-average fair value of stock appreciation rights granted during the six months
ended June 30, 2008 was $8.59. There were no stock appreciation rights granted in the six-month
period ended June 30, 2007.
As of June 30, 2008, total unrecognized stock-based compensation cost related to unvested
stock appreciation rights was $4,673,000, which is expected to be expensed over a weighted-average
period of 3.71 years.
Restricted Stock Awards and Units: Aprias incentive plan provides for the granting of
restricted stock and restricted stock units to its non-employee directors and employees (limited to
executive management). Such awards generally require that certain performance conditions and
service conditions be met before the awards will vest.
16
The following table summarizes the activity for restricted stock awards and units for the six
months ended June 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Weighted-Average |
|
|
|
or |
|
|
Grant-Date |
|
|
|
Share Units |
|
|
Fair Value |
|
Nonvested restricted stock awards and units at January 1, 2008 |
|
|
640,871 |
|
|
$ |
29.73 |
|
Granted |
|
|
423,890 |
|
|
$ |
21.35 |
|
Vested and released |
|
|
(156,274 |
) |
|
$ |
31.04 |
|
Forfeited |
|
|
(17,752 |
) |
|
$ |
25.54 |
|
|
|
|
|
|
|
|
|
Nonvested restricted stock awards and units at June 30, 2008 |
|
|
890,735 |
|
|
$ |
25.59 |
|
The weighted-average fair value of restricted stock awards and units granted during the six
months ended June 30, 2008 and 2007 was $21.35 and $30.33, respectively. There were 372,710 awards
granted in the six month period ended June 30, 2007. Restricted stock awards or units released
during the six months ended June 30, 2008 and 2007 were 156,274 and 108,491 shares, respectively,
and the total intrinsic value was $3,357,000 for both periods, respectively.
As of June 30, 2008, total unrecognized stock-based compensation cost related to unvested
restricted stock awards and units was $15,006,000, which is expected to be expensed over a
weighted-average period of 1.67 years.
NOTE 10 INCOME TAXES
The
Companys effective tax rate was 39.8% for the three months ended June 30, 2008 compared
with 38.7% for the three months ended June 30, 2007. The Companys effective tax rate was 39.8%
for the six months ended June 30, 2008 compared with 37.9% for the six months ended June 30, 2007.
A reconciliation of the beginning and ending balances of the gross liability for unrecognized
tax benefits at June 30, 2008 is as follows (in thousands):
|
|
|
|
|
Total gross unrecognized tax benefits at December 31, 2007 |
|
$ |
115,960 |
|
Additions for tax positions related to the current year |
|
|
1,271 |
|
Additions for tax positions related to prior years |
|
|
1,822 |
|
Reductions for tax positions related to prior years |
|
|
(8,647 |
) |
Settlements |
|
|
(1,158 |
) |
Reductions due to lapse in statute of limitations |
|
|
(1,281 |
) |
Other |
|
|
(31 |
) |
|
|
|
|
Total gross unrecognized tax benefits at June 30, 2008 |
|
$ |
107,936 |
|
|
|
|
|
Total gross unrecognized tax benefits of $107,936,000 is reflected on the Companys June 30,
2008 balance sheet as follows: (a) $18,090,000 included in income taxes payable and other
non-current liabilities and (b) $89,846,000 included in deferred income taxes.
As of June 30, 2008, the amount of unrecognized tax benefits which, if ultimately recognized,
would affect the effective tax rate in a future period is $15,055,000 (net of related tax
benefits). The $15,055,000 unrecognized tax benefits amount is inclusive of $3,637,000 of
penalties and interest (net of related tax benefits).
Based on purchase accounting rules at June 30, 2008, unrecognized tax benefits of $79,259,000
(net) related to Coram, Inc. (Coram) would, if ultimately recognized, only impact goodwill
(versus the Companys effective tax rate). However, upon adoption of SFAS No. 141(R), the entire
$79,259,000 of unrecognized tax benefits related to Coram would, if ultimately recognized, affect
the Companys effective tax rate in a future period.
As of June 30, 2008, it is reasonably possible that unrecognized tax benefits could be
increased or decreased by the following estimated amounts within the 12-month rolling period ending
June 30, 2009.
|
|
|
Aggregate gross increase of $2,500,000 for interest and penalties primarily related to
other tax uncertainties taken in prior years and state tax uncertainties involving tax
filing positions. The gross increase is an annual expense which will be accrued until the
tax uncertainties or related tax uncertainties (in the case of interest and penalties) are
extinguished through such means as audit settlements, payment, or the expiration of
statutes of limitations. |
|
|
|
Aggregate gross decrease of $2,900,000 related to the timing uncertainty for when
certain deductions should be recognized for tax return purposes, allocation of expenses
between affiliates, and state tax uncertainties. Ultimate realization of this decrease is
dependent upon the occurrence of certain events (including the completion of audits by tax
agencies and expiration of statutes of limitations). |
17
Interest expense and penalties related to unrecognized tax benefits are recognized as part of
the provision for income taxes. Gross interest and penalties of $5,912,000 are provided for within
the liability for unrecognized tax benefits as of June 30, 2008.
The Company files federal and state income tax returns in jurisdictions with varying statutes
of limitations expiration dates. The calendar 2004 through 2007 tax years generally remain subject
to examination by tax authorities. The Internal Revenue Service recently completed its examination
of the Companys calendar 2005 and 2006 federal income tax returns. Certain state tax agencies are
currently examining the calendar tax years 2001 through 2006.
As
of June 30, 2008, federal net operating losses
(NOLs) of approximately $113,784,000 are
available to offset future federal taxable income. Such NOLs will expire at various times and in
varying amounts during our calendar 2024 through 2026 tax years. These NOLs were acquired in
connection with the Companys Coram acquisition and are subject to an annual utilization limitation
of approximately $18,081,000 as required by Section 382 of the Internal Revenue Code of 1986, as
amended (the Code). Additionally, the Companys ability to utilize federal tax NOLs and certain
acquisition-related state tax NOLs may be further limited due to certain tax rules involving the
exchange of Coram stock for its debt and associated interest. These debt for stock exchanges
occurred in Corams 2000 through 2002 tax years.
Additionally, Corams NOLs, tax assets and other attributes could be subject to substantial
utilization limitations due to previous Section 382 ownership changes which may have occurred prior
to the Companys acquisition of Coram. In general, an ownership change, as defined by Section 382
of the Code, occurs when a transaction or series of transactions over a three-year period results
in an ownership change of more than 50 percentage points of the outstanding stock of a company. The
Company is currently analyzing whether a Section 382 ownership change occurred prior to its
December 2007 acquisition of Coram and the impact, if any, that such an ownership change could have
on NOL carryforwards, tax assets and other tax attributes.
Net income taxes paid for the six-month periods ended June 30, 2008 and 2007 amounted to
$4,404,000 and $11,583,000, respectively.
NOTE 11 PER SHARE AMOUNTS
The following table sets forth the computation of basic and diluted per share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
June 30, |
|
(in thousands, except per share data) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
23,155 |
|
|
$ |
19,251 |
|
|
$ |
43,927 |
|
|
$ |
40,101 |
|
Numerator for basic and diluted per share amounts net income available to
common stockholders |
|
$ |
23,155 |
|
|
$ |
19,251 |
|
|
$ |
43,927 |
|
|
$ |
40,101 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic per share amounts weighted average shares |
|
|
43,885 |
|
|
|
43,650 |
|
|
|
43,857 |
|
|
|
43,381 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee stock options and awards dilutive potential common shares |
|
|
289 |
|
|
|
582 |
|
|
|
316 |
|
|
|
729 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted per share amounts adjusted weighted average shares |
|
|
44,174 |
|
|
|
44,232 |
|
|
|
44,173 |
|
|
|
44,110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per common share |
|
$ |
0.53 |
|
|
$ |
0.44 |
|
|
$ |
1.00 |
|
|
$ |
0.92 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per common share |
|
$ |
0.52 |
|
|
$ |
0.44 |
|
|
$ |
0.99 |
|
|
$ |
0.91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee stock options excluded from the computation of diluted per share amounts: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares for which exercise price exceeds average market price of common stock |
|
|
4,263 |
|
|
|
1,033 |
|
|
|
3,931 |
|
|
|
1,521 |
|
Average exercise price per share that exceeds average market price of common stock |
|
$ |
27.06 |
|
|
$ |
32.65 |
|
|
$ |
27.14 |
|
|
$ |
31.93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18
NOTE 12 COMMITMENTS AND CONTINGENCIES
Litigation: The Company is the defendant in a purported California class action lawsuit
asserting blanket claims of liability under various California employee protection statutes and
regulations relating to payment of regular and overtime wages, the timeliness of such payments, the
maintenance and provision of access to required payroll records, and the provision of meal and rest
periods. The original claim was filed by Jesus Venegas on February 21, 2006 in the California
Superior Court for the County of San Francisco (Case No. CGC 06 449669). The complaint, as
amended, seeks compensatory damages in an unspecified amount as well as other relief on behalf of a
purported class consisting of substantially all of the Companys delivery drivers in the State of
California. The Company has answered the complaint denying all material allegations and asserting a
number of affirmative defenses. The Company has successfully pursued motions for summary
adjudication eliminating certain tort based claims and claims for unjust enrichment and declaratory
relief. Based on the investigation of the allegations made to date, the Company believes there are
meritorious defenses to the remaining claims and intends to continue a vigorous defense of the
lawsuit. The Court has not established a trial date and has indicated that the issue of whether
the case may be certified as a class action is likely to be determined at a hearing which it
expects to hold in early 2009. Until a final decision is made with respect to the plaintiffs class
action allegations, no assurances can be given that the ultimate disposition of this case will not
have a material adverse effect on the Companys financial condition or results of operations.
The
Company has also been served with two complaints seeking to enjoin
the proposed Merger as discussed in Note 2.
The first complaint was filed on June 24, 2008 by Alaska Ironworkers Pension Trust, On Behalf
of Itself and All Others Similarly Situated, in the Superior Court of the State of California,
County of Orange, Case No. 30-2008-00078710. The complaint names the Company and its directors as
defendants, and asserts a single cause of action for breach of fiduciary duty and aiding and
abetting against all defendants. The complaint seeks certification of a class of all common
stockholders of the Company who are being and will be harmed by defendants alleged actions; a
declaration that the proposed transaction is in breach of defendants fiduciary duties, and,
therefore, unlawful and unenforceable; an order enjoining defendants and others from consummating
the proposed transaction; an order directing the individual defendants to exercise their fiduciary
duties to obtain a transaction in the best interests of the Companys stockholders; rescission of
the proposed transaction to the extent already implemented; recovery of costs of suit, including
attorneys fees; and other relief.
The second complaint was filed on July 2, 2008 by Bruce Ellis, On Behalf of Himself and All
Others Similarly Situated, in the Superior Court of the State of California, County of Orange, Case
No. 30-2008-00081027. The complaint names the Company, the Companys directors, and Blackstone
Group LP as defendants, and asserts two (2) causes of action: (1) breach of fiduciary duty against
the individual defendants, and (2) aiding and abetting the individual defendants breach of
fiduciary duty against Blackstone Group LP. The complaint seeks certification of a class of all
common stockholders of the Company who are being and will be harmed by defendants alleged actions;
a declaration that the proposed transaction is in breach of defendants fiduciary duties, and,
therefore, unlawful and unenforceable; an order enjoining defendants and others from consummating
the proposed transaction; an order enjoining the defendants from holding a shareholder vote on the
proposed transaction until curative disclosures are made; an order directing the individual
defendants to exercise their fiduciary duties to obtain a transaction which is in the best
interests of the Companys stockholders; rescission of the proposed transaction to the extent
already implemented; imposition of a constructive trust, in favor of plaintiff, upon any benefits
improperly received by defendants; recovery of costs of suit, including attorneys fees; and other
relief.
On July 15, 2008, the Court issued an Order on Consolidation of Related Actions and
Appointment of Lead Counsel, where the Court, among other things, consolidated the above actions,
as well as other current or future actions arising out of the same set of facts that are filed in
or transferred to the Court, into a single action, titled In re Apria Healthcare Group Inc.
Shareholder Litigation, Lead Case No. 30-2008-00078710. Coughlin, Stoia, Geller, Rudman & Robbins
LLP was appointed as lead counsel for plaintiffs in the consolidated action. The Court further
ordered plaintiffs to file a consolidated complaint within 30 days of the July 24, 2008 filing with
the SEC of the Companys preliminary proxy statement on Schedule 14A.
The parties have stipulated to extend this deadline to September 22, 2008, and
plaintiffs have not filed a consolidated complaint as of the date of the filing of this
Form 10-Q.
Pursuant to the July 15, 2008
order, the consolidated complaint will supersede all complaints filed in any consolidated action,
and defendants shall respond to the consolidated complaint pursuant to a briefing schedule to be
agreed upon by the parties and approved by the Court. Also pursuant to the order, defendants are
not required to, and have not, responded to the foregoing complaints.
The Company is also engaged in the defense of certain claims and lawsuits arising out of the
ordinary course and conduct of its business, the outcomes of which are not determinable at this
time. Insurance policies covering such potential losses, where such coverage is cost effective, are
maintained. In the opinion of management, any liability that might be incurred upon the resolution
of these claims and lawsuits will not, in the aggregate, have a material adverse effect on the
Companys financial condition or results of operations.
19
Medicare and Medicaid Reimbursement: There are a number of provisions contained within recent
legislation or proposed legislation that affect or may affect Medicare reimbursement polices for
items and services provided. The Company cannot be certain of the ultimate impact of all legislated
and contemplated changes, and therefore, cannot provide assurance that these changes will not have
a material adverse effect on the Companys financial condition or results of operations.
Supplier Concentration: Currently, approximately 75.2% of purchases for patient service
equipment and supplies are from four vendors. Although there are a limited number of suppliers,
management believes that other vendors could provide similar products on comparable terms. However,
a change in suppliers could cause delays in service delivery and possible losses in revenue, which
could adversely affect the Companys financial condition or operating results.
Guarantees and Indemnities: From time to time, certain types of contracts are entered into
that contingently require indemnification of parties against third party claims. These contracts
primarily relate to (i) certain asset purchase agreements, under which indemnification may be
provided to the seller of the business being acquired; (ii) certain real estate leases, which may
require indemnification to property owners for environmental or other liabilities and other claims
arising from use of the applicable premises; and (iii) certain agreements with officers, directors
and employees, which may require indemnification of such persons for liabilities arising out of
their relationship with the Company.
The terms of such obligations vary by contract and in most instances a specific or maximum
dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be
reasonably estimated until a specific claim is asserted. Consequently, no liabilities have been
recorded for these obligations on the balance sheets for any of the periods presented.
NOTE 13 SUBSEQUENT EVENTS
On
September 2, 2008, the Company repurchased $249.8 million in
aggregate principal of the senior notes, representing approximately
99.91% of the outstanding principal amount. $0.2 million in aggregate
principal amount of
the senior notes remains outstanding. This repurchase also triggered
a tax liability of $30.0 million. The repurchase of
$249.8 million was funded by a draw down on our liquidity credit
facility, entered into on June 18, 2008.
20
|
|
|
ITEM 2. |
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
This Managements Discussion and Analysis of Financial Condition and Results of Operations is
intended to assist in understanding and assessing the trends and significant changes in our results
of operations and financial condition. Historical results may not indicate future performance. Our
forward-looking statements reflect our current views about future events, are based on assumptions
and are subject to known and unknown risks and uncertainties that could cause actual results to
differ materially from those contemplated by these statements. Factors that may cause differences
between actual results and those contemplated by forward-looking statements include, but are not
limited to, those discussed in Part II, Item 1A, Risk Factors, of our Annual Report on Form 10-K/A
for the fiscal year ended December 31, 2007. As used in this Managements Discussion and Analysis
of Financial Condition and Results of Operations, the words we, our, us and the Company
refer to Apria Healthcare Group Inc. and its consolidated subsidiaries. This Managements
Discussion and Analysis of Financial Condition and Results of Operations should be read in
conjunction with our condensed consolidated financial statements and related notes included in this
report.
All information set forth in this Item 2 Managements Discussion and Analysis with respect
to 2007 includes the effects thereon of the restatement, of our condensed consolidated statements
of income for the three and six months ended June 30, 2007, if any. See Note 3 Restatement of
Consolidated Financial Statements contained in the Notes to Unaudited Condensed Consolidated
Financial Statements in Item 1 for a more detailed discussion of the restatement.
We operate in the home healthcare segment of the healthcare industry and provide services in
the home respiratory therapy, home infusion therapy and home medical equipment areas. In all three
service lines, we provide patients with a variety of clinical and administrative support services
and related products and supplies, most of which are prescribed by a physician as part of a care
plan. We provide these services to patients through approximately 550 locations throughout the
United States.
We evaluate operating results on a service line basis and, therefore, view each service line
as a reporting unit. For financial reporting purposes, all our service lines are aggregated into
one reportable segment in accordance with the aggregation criteria of SFAS No. 131, Disclosures
about Segments of an Enterprise and Related Information.
Recent Developments. On June 18, 2008, we entered into an Agreement and Plan of Merger (the
Merger Agreement) with Sky Acquisition LLC, a Delaware limited liability company (Buyer) and
Sky Merger Sub Corporation, a Delaware corporation and wholly-owned subsidiary of Buyer (Merger
Sub). Buyer is controlled by a private investment fund affiliated with The Blackstone Group
(Blackstone), which is providing a portion of the funding for the transaction.
The Merger Agreement provides that, upon the terms and subject to the conditions set forth in
the Merger Agreement, Merger Sub will merge with and into the Company (the Merger) with the
Company continuing as the surviving corporation and a wholly-owned subsidiary of Buyer. As of the
effective time of the Merger, each issued and outstanding share of our common stock will be
cancelled and converted into the right to receive $21.00 in cash, without interest and less
applicable withholding taxes (the Merger Consideration). Buyer and Merger Sub have obtained
equity and debt financing commitments for the transactions contemplated by the Merger Agreement,
the aggregate proceeds of which will be sufficient for Buyer to pay the aggregate Merger
Consideration and all related fees and expenses. Debt financing commitments of $1.15 billion have
been provided by a syndicate comprised of Bank of America, Wachovia Bank, and Barclays Capital.
Consummation of the Merger is not subject to a financing condition, but is subject to various other
conditions, including approval of the Merger Agreement by our stockholders, expiration or
termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended (the HSR Act), accuracy of the representations and warranties of the Company and
other customary closing conditions. On July 8, 2008, we received notice that the federal antitrust
authorities have granted early termination of the waiting period under the HSR Act. The parties
expect to close the transaction later in 2008.
We have made various representations and warranties and agreed to certain covenants in the
Merger Agreement, including covenants relating to the Companys conduct of its business between the
date of the Merger Agreement and the closing of the Merger, governmental filings and approvals,
public disclosures and other matters.
The Merger Agreement contains certain termination rights for both us and the Buyer. The Merger
Agreement provides that, upon termination under specified circumstances, we would be required to
pay Buyer a termination fee. The Merger Agreement further provides that, upon termination under
other specified circumstances, Buyer would be required to pay us a reverse termination fee. The
reverse termination fee potentially payable by Buyer is guaranteed by an investment fund affiliated
with Blackstone, in a separate limited guarantee.
21
On June 18, 2008, the Company entered into a $280 million credit facility pursuant to the
Credit Agreement. On September 2, 2008 proceeds of the new
credit facility were used to fund repurchases of
the Companys 3 3/8% Convertible Senior Notes due 2033 and will
be used to pay certain tax liabilities related
thereto. The loans under the credit facility bear interest at a rate of eleven per cent (11%) per
year with a maturity date of March 1, 2009. In addition, the Company paid usual and customary bank
fees in connection with entering into the Credit Agreement. The Credit Agreement includes
restrictions on the Company regarding additional indebtedness, business operations, liens,
transfers and sales of assets, and transactions with affiliates. The Credit Agreement also contains
customary events of default which would permit the lenders to accelerate payments under the
Credit Agreement if not cured within applicable grace periods, including the failure to make timely
payments under the Credit Agreement and the failure to follow certain
covenants. As of June 30,
2008, the Company was in compliance with all covenants, but, due to the
non-timely filing of the Company’s quarterly report on Form
10-Q for the period ended June 30, 2008, the Company would have
been in default of the reporting covenants under the Credit Agreement
on August 15, 2008. However, the
Company’s lenders executed a waiver on August 14, 2008, which
extended the filing requirement from 45 to 90 days. Upon the
filing of this quarterly report on Form 10-Q for the
period ended June 30, 2008,
the Company will have remedied the
non-compliance with reporting requirements under its Credit
Agreement.
On
September 2, 2008, the Company repurchased $249.8 million in aggregate
principal of its senior notes representing approximately 99.91% of the
outstanding principal amount. $0.2 million in aggregate principal amount of the
senior notes remains outstanding.
On August 26,
2008, Apria received a notice of default from the trustee under the indenture
governing the senior notes regarding Apria’s failure to deliver its
Quarterly Report on Form 10-Q for the period ended June 30, 2008 within
the specified time period. Pursuant to the indenture, failure by Apria to
comply with such reporting requirements will become an event of default if not
remedied within 60 days after the date on which written notice of such
failure, requiring Apria to remedy the same, is given to Apria by the trustee,
and the senior notes, together with accrued and unpaid interest thereon, shall
become due and payable immediately upon notice to the Company from the Trustee
or the holders of not less than 25% in aggregate principal amount of the senior
notes then outstanding. Upon the filing of this
quarterly report on Form 10-Q for the period ended
June 30, 2008, the
Company will have remedied the default under its senior notes.
Strategy. Our strategy is to position ourselves in the marketplace as the low cost, quality
provider of a broad range of home healthcare services to managed care and government customers. The
specific elements of our strategy are to:
|
|
|
achieve strong organic sales growth and increase market share; |
|
|
|
|
leverage our nationwide infrastructure to reduce costs and expand profits; |
|
|
|
|
deliver superior customer service; |
|
|
|
|
attract, develop and advance leaders within the Company; |
|
|
|
|
operate our business ethically; and |
|
|
|
|
maintain independent accreditation at all locations. |
Critical Accounting Policies. We consider the accounting policies that govern revenue
recognition and the determination of the net realizable value of accounts receivable to be the most
critical in relation to our consolidated financial statements. These policies require the most
complex and subjective judgments of management. Additionally, the accounting policies related to
goodwill, long-lived assets, share-based compensation and income taxes require significant
judgment. These policies are presented in detail in the Managements Discussion and Analysis of
Financial Condition and Results of Operations section in our Annual Report on Form 10-K/A for the
year ended December 31, 2007.
Government Regulation
We are subject to extensive government regulation, including numerous laws directed at
regulating reimbursement of our products and services under various government programs and
preventing fraud and abuse, as more fully described below. We maintain certain safeguards intended
to reduce the likelihood that we will engage in conduct or enter into arrangements in violation of
these restrictions. Corporate contract services and legal department personnel review and approve
written contracts, such as billing contracts and discount agreements, subject to these laws. We
also maintain various educational and audit programs designed to keep our managers updated and
informed regarding developments on these topics and to reinforce to employees our policy of strict
compliance in this area. Notwithstanding these measures, violations of these laws and regulations
may still occur.
Medicare and Medicaid Reimbursement Revenues. In 2007, approximately 35% of our revenues were
reimbursed by the Medicare and state Medicaid programs. For the six months ended June 30, 2008 and
2007, Medicare and Medicaid revenues represented 32% and 35% of our total net revenue,
respectively. For the full year of 2008, we estimate that the percentage of our revenues
reimbursed under arrangements with Medicare and Medicaid will be approximately 31%. No other
third-party payor represented more than 9% of our total net revenues for 2007 and for the quarter
ended June 30, 2008. The majority of our revenues are derived from rental income on equipment
rented and related services provided to patients, sales of equipment, supplies and pharmaceuticals
and other items we sell to patients for patient care under fee-for-service arrangements. Revenues
derived from capitation arrangements represented 8% and 11% of net revenues for the quarters ended
June 30, 2008 and 2007, respectively.
22
Medicare Reimbursement. There are a number of historic and ongoing legislative and regulatory
activities in Congress and at the Centers for Medicare and Medicaid Services (CMS) that affect or
may affect Medicare reimbursement policies for products and services we provide. Specifically, a
number of important legislative changes that affect our business were included in the Medicare
Prescription Drug, Improvement, and Modernization Act (MMA), which was signed into law in
December 2003, the Deficit Reduction Act of 2005 (DRA), which was signed into law in February
2006, and most recently, the Medicare Improvements for Patients and Providers Act of 2008
(MIPPA), which became law on July 15, 2008. These Acts and their implementing regulations and
guidelines contain numerous provisions that were significant to us and continue to have an impact
on our operations today, as described below:
DMEPOS Competitive Bidding. The MMA required implementation of a competitive bidding program
for certain durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) items. By
statute, CMS was required to implement the DMEPOS competitive bidding program over time, with the
first phase (Round 1) of competition occurring in portions of 10 of the largest metropolitan
statistical areas (called competitive bidding areas or CBAs) in 2007, launch of the program in
2008 and in 70 additional markets in 2009, and in additional markets after 2009.
In 2007 and 2008, CMS accepted and reviewed bids to begin Round 1 on July 1, 2008. CMS
offered us contracts in several CBAs in Round 1; we accepted the contracts for certain product
categories and declined others due to unacceptably low payment amounts in certain markets, which
would not adequately cover the cost of providing quality service to our patients in those areas.
Winning contract suppliers were to begin providing services under Round 1 on July 1, 2008.
The bidding process for Round 1 was controversial and complex, which resulted in deadline
extensions. Moreover, CMS was subject to numerous lawsuits seeking a delay of Round 1. Then on
July 15, 2008, MIPPA was enacted which, among other provisions, delays the DMEPOS competitive
bidding program by requiring that Round 1 competition commence in 2009, and requires a number of
program reforms prior to CMS relaunching the program. As a result, contracts that were awarded
under Round 1 have been terminated and the contracting process will need to be restarted through a
re-bidding process in 2009. In addition, CMS has publicly announced that currently Medicare
beneficiaries in the fee-for-service Medicare program may use any provider in any geographic area,
including the CBAs, to obtain home medical equipment and oxygen therapy services and products. CMS
also expects to notify Medicare beneficiaries in all former CBAs of this right and the delay of the
program by direct mail by August 2008.
Under MIPPA, the initial CBAs and product categories subject to rebidding will be very similar
to those of Round 1. One difference, however, is that one of the 10 CBAs originally designated,
Puerto Rico, will be excluded from the competitive bidding program. We do not service Puerto Rico.
MIPPA also excludes Negative Pressure Wound Therapy Pumps and Related Supplies and Accessories as a
competitive bidding product category in Round 1 and permanently excludes Complex Rehabilitative
Power Wheelchairs and Related Accessories as a potential competitive bidding product category.
The revenue associated with the items subject to competitive bidding in what was to be the
initial year of the program represents less than 2% of our 2007 total net revenues. CMS estimated
the Round 1 Single Payment Amounts represented an average payment cut of approximately 26% from the
existing fee schedule for the impacted product categories. However, since the adoption of MIPPA
and the required delay in re-bidding, the actual impact of competitive bidding on our total net
revenues will likely be different given the fact that a re-bidding process could result in pricing
discounts different than what CMS published for Round 1. Under the Single Payment Amounts for
Round 1, if the program had continued, competitive bidding payment reductions in 2008 would have
resulted in a decline of approximately 0.4% in our 2008 total net revenues from the level we would
have expected if competitive bidding had not been in effect.
Notwithstanding the changes MIPPA requires, competitive bidding imposes a significant risk to
DMEPOS suppliers. Under the rules governing Round 1, if a DMEPOS supplier operating in a CBA is
not awarded a contract for that CBA, the supplier generally will not be able to bill and be
reimbursed by Medicare for DMEPOS items supplied in that CBA for the time period covered by the
competitive bidding program unless the supplier meets certain exceptions or acquires a winning
bidder. Because the applicable statutes mandate financial savings from the competitive bidding
program, a winning contract supplier will receive lower Medicare payment rates under competitive
bidding than the otherwise applicable DMEPOS fee schedule rates. As competitive bidding is phased
in across the country under the revised MIPPA implementation schedule, we will likely experience a
reduction in reimbursement, as will most if not all other DMEPOS suppliers in the impacted areas.
In addition, there is a risk that the new competitive bidding prices will become a benchmark for
reimbursement from private payors. MIPPA does not prevent CMS from adjusting prices for DMEPOS
items in non-bid areas; however, before using its authority to adjust prices in non-bid areas,
MIPPA requires that CMS issue a regulation that specifies the methodology to be used and consider
how prices through competitive bidding compare to costs for those items and services in the non-bid
areas. At this time, it is unclear what specific changes CMS will make to the bidding process and
the competitive bidding program as a whole to address the concerns that led to the passage of
MIPPA, and we cannot quantify what negative impact, if any, the revised program will have upon our
revenue or operations once the program is reinitiated.
23
Nevertheless, we believe that our geographic coverage, clinical marketing programs and
purchasing strength provide competitive advantages to maintain and enhance market share under
Medicare competitive bidding. However, there is no guarantee that we will be selected as a winning
contract supplier and be awarded a competitive bidding contract by CMS in any phase of the revised
implementation schedule for competitive bidding. Under the current competitive bidding
regulations, if we are not selected as a winning contract supplier for a particular CBA, we will
generally not be allowed to supply Medicare beneficiaries in the CBA with products subject to
competitive bidding, unless we elect to continue to service existing patients under the
grandfathering provision of the final rule or we acquire a winning supplier. Because of our
combination of both managed care and traditional business, we believe we can nevertheless maintain
a favorable overall market position in a particular CBA even if we are not selected as a contract
supplier for a particular CBA.
Medicare Fee Schedule for DMEPOS and CPI Adjustments. In addition to the adoption of the
DMEPOS competitive bidding program, the MMA implemented a five-year freeze on annual consumer price
index (CPI) payment increases for most durable medical equipment (DME) from 2004 to 2008. In
MIPPA, in order to offset the cost of, or pay for the delay in the implementation of the DMEPOS
competitive bidding program, Congress approved a nationwide 9.5% payment reduction in the DMEPOS
fee schedule for those product categories included in Round 1, effective January 1, 2009. These
product categories, could be subjected to a legislated CPI update in 2014, except if the item is
still subject to competitive bidding or CMS has otherwise adjusted the payment rate.
The MIPPA legislation has also implemented nationwide CPI increases beginning in 2009 for
those DMEPOS items that were not subject to competitive bidding in July 2008. Those DMEPOS items
that were not subject to Round 1 competitive bidding will receive a full CPI update each year from
2009 to 2013. In 2014, these items will receive the CPI update plus 2%.
Capped
Rentals and Oxygen Equipment. Under the DRA, beginning with Medicare beneficiaries who received DMEPOS
products and services as of January 2006, ownership of certain DME categorized by CMS in the
capped rental category (e.g., hospital beds, wheelchairs, nebulizers, patient lifts and
continuous positive airway pressure devices) automatically transfers to the Medicare beneficiary at
the end of a maximum rental period. As of January 1, 2006, the maximum rental period became 13
months. Therefore, the first month in which the new policy had an impact on our revenue was
February 2007. In addition, the service and maintenance fee, which had been paid to suppliers
twice yearly after the rental period ended in order to cover various non-equipment service costs
for patients who require use of the equipment, was eliminated for those patients who commenced
service on or after January 1, 2006. However, the DRA provides for additional payments for
maintenance and service of the item for repair parts and labor not covered by a suppliers or
manufacturers warranty. Implementing regulations also imposed other repair and replacement
obligations on suppliers with respect to equipment that does not last the useful lifetime of the
equipment, which CMS has generally defined as being five years.
With respect to oxygen equipment, the DRA converted Medicare reimbursement for oxygen
equipment from an ongoing rental method to a capped rental and rent-to-purchase methodology and
limited reimbursement for rental of oxygen equipment to the current 36-month maximum. The DRA also
mandated that, after the 36-month rental period, the ownership of the equipment would transfer to
the Medicare beneficiary, who would assume primary responsibility for identifying when repairs or
preventive maintenance are needed. The existing implementing regulations to this DRA provision
also limit supplier replacement of oxygen equipment during the rental period, and require suppliers
to replace beneficiary-owned equipment that does not last the useful lifetime of the equipment,
which CMS has generally defined as being five years. However, MIPPA repealed the mandatory title
transfer for oxygen equipment. As a result, the equipment will continue to be owned by the home
oxygen provider for as long as the patients medical need exists, after which time it will be
returned to the home oxygen provider. It is not yet known when CMS will issue new or updated
implementing regulations concerning MIPPAs repeal of mandatory title transfer for oxygen
equipment.
The 36-month rental period was retroactively applied to January 1, 2006 for all beneficiaries
requiring oxygen as of December 31, 2005. Accordingly, January 2009 is the first month in which
the rental cap will impact us. Additional DRA regulations, which remain intact despite the repeal
of mandatory title transfer, established new payment classes for oxygen equipment, including
transfilling and portable equipment, new monthly rental reimbursement rates, and new reimbursement
rates for the delivery of oxygen contents for patient-owned equipment after title to the equipment
transfers. CMS has not published any changes to these rates or policies as a result of MIPPAs
passage but has stated that CMS will update its regulations relating to the DRA in the future. In
its original regulations published in 2007, CMS stated that CMS would annually review the
utilization patterns and fee schedule rates for oxygen and consider whether an adjustment to the
payment rates is needed in order to satisfy the statutory mandate of budget neutrality.
24
Regarding repairs and maintenance of Medicare beneficiary-owned oxygen equipment, the existing
implementing DRA regulations permit payment to suppliers for general maintenance and servicing of
certain patient-owned oxygen equipment every six months, beginning after the first six months the
patient owns the equipment. The existing final rule governing repairs and
maintenance of oxygen equipment limits payment for general maintenance and servicing visits to
30 minutes of labor based on rates the Medicare contractors establish. In its last final rule on
this subject, CMS declined to offer general maintenance and servicing payments for
beneficiary-owned liquid and gas equipment with the exception of a single payment for pick-up and
storage or disposal of such equipment that a beneficiary no longer needs. Due to the recent
passage of MIPPA and the lack of implementing regulations from CMS arising from MIPPA, we cannot
speculate on any changes CMS may make to its repair, maintenance and service or other fee schedules
related to those oxygen patients who reach the cap but do not own their equipment. We may or may
not continue to provide repair and maintenance service on oxygen equipment that has met the cap and
are continuing to evaluate the impact of the changes likely to occur due to both the DRA and MIPPA.
In January 2006, CMS published a final regulation that shifted payment for certain respiratory
assist devices from the frequent and substantial payment category to the capped rental
category. Under frequent and substantial payment, Medicare payment continues for the duration of
time the beneficiary requires the device, while capped rental payment continues for 13 months.
The change in the payment category became effective April 1, 2006. The first claims received for
each Medicare beneficiary with a date of service on or after April 1, 2006, including beneficiaries
with existing rental equipment, are counted as the first rental month in the capped rental period.
Thus, the first month in which the new categorization impacted our revenue was May 2007. Our
estimate for this change in payment categories was a reduction in 2007 revenues of approximately
$2.5 million.
In recent years, there were several legislative and executive branch efforts to further reduce
the maximum rental period for oxygen therapy, equipment and related services. The Presidents
2007, 2008 and 2009 healthcare budget proposals sought to reduce the maximum rental period for
oxygen equipment from the now-mandated 36 months to 13 months, which was recommended by the HHS
Office of Inspector General (OIG) in a limited study of the oxygen benefit published in 2006
entitled Medicare Home Oxygen: Equipment Cost and Servicing. There are other initiatives to
implement a reduction to either the cap period or the monthly payment rate, but it is uncertain
whether any of these initiatives will ultimately be reintroduced and approved by Congress or the
Administration in future years.
Reimbursement for Inhalation and Infusion Therapy Drugs. As a result of MMA, beginning
January 2005, Medicare Part B reimbursement for most drugs, including inhalation drugs, became
based upon the manufacturer-reported average sales price (ASP) (subject to adjustment each
quarter), plus 6%, plus a separate dispensing fee per patient episode. CMS publishes the ASP plus
6% payment levels in the month that precedes the first day of each quarter, and we have no way of
knowing if the quarterly ASPs will increase or decrease since manufacturers report applicable ASP
information directly to CMS. Since 2006, dispensing fees have remained at $57.00 for a 30-day
supply for a new patient, $33.00 for each 30-day supply thereafter, and $66.00 for each 90-day
supply.
The Medicare reimbursement methodology for non-compounded, infused drugs administered through
DME, such as infusion pumps, was not affected by this MMA change. It remains based upon either 95%
of the October 1, 2003 Average Wholesale Price (AWP) or, for those drugs whose AWPs were not
published in the applicable 2003 compendia, at 95% of the first published AWP.
The 2007 Healthcare Common Procedure Coding System (HCPCS) list for Medicare Part B
medications included new codes for certain compounded medications. The coding and reimbursement
changes did not have a material impact on us due to the extremely low volume of patient-specific,
physician-prescribed compounding that was performed by our inhalation pharmacies.
Although CMS had considered issuing a National Coverage Decision for certain inhalation drug
therapies, in the third quarter of 2007, CMS issued a National Coverage Decision that stated that
no national coverage policy was appropriate at that time. Rather, CMS stated that it would
continue to defer decisions about the medical necessity of individual respiratory drugs to the
local contractors. Thereafter, in April of 2008, the DME Medicare Administrative Contractors
finalized a proposed local coverage determination policy for several respiratory drugs, including
Xopenex®1 and DuoNeb®2. Each of these two drugs was subjected to a separate
least costly alternative (LCA) policy which would have changed the reimbursement methodology
in a way that would effectively have eliminated Medicare beneficiary access to these drugs which
are frequently used to treat Chronic Obstructive Pulmonary Disease (COPD). After complaints were
filed by Medicare beneficiaries in the Federal District Court of the District of Columbia, CMS
announced that it planned to withdraw the LCA for Xopenex and take no LCA action on that product
until at least January 1, 2009. After separate litigation was filed, the LCA for DuoNeb was
postponed until November 1, 2008. Both cases are still being litigated. At this time, we cannot
predict how these court actions will be resolved. Additionally, if or when CMS reconsiders
these issues, we do not know how any of these decisions might impact our operations, but
future decisions with respect to the coverage of inhalation drugs may have a material adverse
impact on us.
|
|
|
1 |
|
Xopenex is a registered trademark of Sepracor, Inc. |
|
2 |
|
DuoNeb is a registered trademark of Dey Labs, LLC. |
25
In 2007, there also were changes to the reimbursement methodology for certain inhalation
drugs. Beginning in the third quarter of 2007, CMS began reimbursing providers of Xopenex and
albuterol a blended ASP for these two inhalation drugs. On December 29, 2007, the President signed
into law the Medicare, Medicaid, and State Childrens Health Insurance Program Extension Act of
2007, which partially reversed the CMS regulatory decision regarding Xopenex and albuterol.
Beginning on April 1, 2008, Medicare began to reimburse providers for Xopenex by blending the
average sales prices of Xopenex and albuterol, but it no longer reimbursed providers for albuterol
at the blended price. Rather, albuterol is reimbursed using an albuterol-only ASP.
We estimate that these changes to inhalation drug reimbursement will result in a total
incremental $5 million decline in revenue for 2008. However, we have undertaken strategies
intended to partially mitigate this negative impact.
A limited number of infusion therapies, supplies and equipment are covered by Medicare Part B.
The MMA, through the new Medicare Part D program, provided expanded coverage for certain home
infusion therapy drugs, but excluded coverage for the corresponding supplies and clinical services
needed to safely and effectively administer these drugs. We have contracted with a limited number
of Medicare Part D prescription drug plans in order to provide continuity of care for certain
patients.
Due to ongoing Part D coverage and payment issues associated with home infusion therapy, the
industry is continuing to work with CMS and Congress to rectify the Medicare coverage and payment
limitations that limit patient and referral source access to quality home infusion therapy
services. Bills were introduced in Congress in both the 109th and 110th Congress to consolidate
home infusion therapy coverage under Part B. This legislation would provide for Medicare infusion
benefit coverage in a more comprehensive manner that is analogous to how the therapy is covered by
the managed care sector. Industry representatives continue to present the cost-saving advantages
of home infusion therapy to Members of Congress and the Administration. At this time, we cannot
assess whether similar legislation may be introduced in the future or whether it will become law.
Enrollment and Accreditation of DME Suppliers. While we support the elimination of fraudulent
suppliers and are working with CMS to support these initiatives, we also note that a number of
initiatives and developments with respect to the enrollment and accreditation of providers could
impact our operations in the future. For example, accreditation is mandatory for suppliers who
wish to participate in the Medicare competitive bidding program. Accreditation also is becoming
mandatory as a condition of enrollment and continuing participation as a Medicare DME supplier, not
just for those DME suppliers participating in the Medicare competitive bidding program. We and all
of our branches currently are accredited. If we or any of our branches lose accreditation, or if
any of our new branches are unable to become accredited, that could have a material adverse effect
on our results of operations, cash flow and capital resources.
Another example
is that in July 2007, CMS issued a proposed rule requiring all DMEPOS
suppliers to provide CMS with a surety bond of at least $65,000 for each National Provider
Identifier the supplier holds. The rule would ensure that Medicare can recover any erroneous
payment amounts or civil money penalties up to $65,000 that result from fraudulent or abusive
supplier billing practices. There is a similar legislative proposal, introduced on February 7,
2008 in the Senate, entitled the Medicare Fraud Prevention Act of 2008, which would increase
financial penalties and prison sentences for certain civil and criminal violations of the Social
Security Act, including making false statements and violating the federal anti-kickback statute.
The proposed Act would also increase the amount of the surety bond requirement for DME suppliers to
$500,000. We cannot predict whether this legislation, or some revised form of it, will or will not
become law.
In January 2008, CMS proposed regulations expanding and strengthening enrollment requirements
which DME suppliers must meet to establish and maintain Medicare billing privileges. These
revisions would impose additional requirements in the areas of provider insurance, marketing
practices, document retention, facility location, and hours of operation. We submitted comments to
the proposal prior to the March 25, 2008 deadline. We believe there will not be any material
impact on us if the proposal is finalized in its current form. It is uncertain whether any or all
of these proposed regulations will be finalized, however, and we cannot predict or estimate the
impact of the final changes, if any.
In June 2008, the Seniors and Taxpayers Obligation Protection Act (STOP Act) was introduced
in the U.S. Senate. The bill, if implemented, would require the Secretary of HHS to implement
procedures to change the current system of using Social Security numbers as the Medicare
Beneficiary Identifier (MBI) in an effort to reduce fraud and identity theft among seniors. This
measure also establishes prepaid fraud detection methods, which include pre-enrollment site visits
for high risk areas and prepayment claim edits to detect submissions that are most likely
fraudulent. This bill also contains a surety bond requirement for DME suppliers. We
cannot predict whether this STOP Act bill, or an amended version, will or will not become law
or otherwise negatively impact our operations.
26
Inherent Reasonableness. The Balanced Budget Act of 1997 granted authority to HHS to increase
or reduce Medicare Part B reimbursement for home medical equipment, including oxygen, by up to 15%
each year under an inherent reasonableness authority. Pursuant to that authority, CMS published
a final rule that established a process by which such adjustments may be made. The rule applies to
all Medicare Part B services except those paid under a physician fee schedule, a prospective
payment system, or a competitive bidding program. Neither HHS nor CMS has issued any subsequent
communication or information for several years and, therefore, we cannot predict whether or when
HHS would exercise its authority in this area or predict any negative impact of any such change.
Use of Recovery Audit Contractors. The MMA directed HHS to conduct a 3-year demonstration
program using Recovery Audit Contractors (RACs) to detect and correct improper payments in the
Medicare fee-for-service program. The demonstration program began in March 2005 and ended in March
2008 in California, Florida, and New York. The Report was issued in 2008 and CMS plans to phase in
the new RACs gradually beginning in the summer of 2008 through December 2009. The Tax Relief and
Health Care Act of 2006 requires HHS to establish the RAC initiative as a permanent, nationwide
program by no later than January 1, 2010. We cannot at this time quantify any negative impact that
the expansion of the RAC program may have on us.
Incentives for the Expansion of Medicare Part C (Medicare Advantage). The MMA included
financial incentives for managed care plans to expand their provision of Medicare Advantage plans
in 2006 in an effort to attract more Medicare beneficiaries to managed care models. We maintain
contracts to provide home respiratory therapy, home infusion therapy services, home medical
equipment and related services to a significant number of managed care companies who maintain
Medicare Advantage plans nationwide. Although MIPPA reduces certain Medicare Part C incentives,
Medicare Advantage plans may continue to be attractive alternatives to traditional Medicare
fee-for-service for those Medicare beneficiaries who choose them and the Company intends to
continue to contract with them.
Beneficiary Access to Power Mobility Devices. In late 2006, CMS revised the Local Coverage
Determination (LCD) for power mobility devices resulting in reductions to the Medicare power
mobility devices fee schedule of about 15%. The initial changes took effect November 15, 2006.
The reduction in our revenues for 2007 resulting from these fee schedule changes was approximately
$1 million. The industry also believes that Medicare beneficiary access to power mobility will be
restricted by this LCD and therefore has requested revisions to the fee schedule.
We cannot estimate the combined possible impact of all legislative, regulatory and
contemplated reimbursement changes that could have a material adverse effect on our results of
operations, cash flow, and capital resources. Moreover, our estimates of the impact of certain of
these changes appearing in this Government Regulation section are based on a number of
assumptions and are subject to uncertainties and there can be no assurance that the actual impact
was not or will not be different from our estimates.
Medicaid Reimbursement. State Medicaid programs implement reimbursement policies for the
items and services we provide that may or may not be similar to those of the Medicare program.
Budget pressures on these state programs often result in pricing and coverage changes that may have
a detrimental impact on our operations. States sometimes have adopted alternative pricing
methodologies for certain drugs, biologicals, and home medical equipment under their Medicaid
programs that reduce the level of reimbursement received by us without a corresponding offset or
increase to compensate for the service costs incurred. Historically, we frequently elected to stop
accepting new Medicaid patient referrals for the affected drugs, biologicals, and home medical
equipment. Should these types of changes occur in the future, we may or may not elect to make
similar decisions. Other states have expanded coverage for certain products and services. We
cannot predict whether other states will consider reductions as well and whether any such changes
could have a material adverse effect on our results of operations, cash flow and capital resources.
HIPAA. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is comprised
of a number of components pertaining to the privacy and security of certain patient health
information, as well as the standard formatting of certain electronic health transactions. Many
states have similar, but not identical, restrictions. Existing and any new laws or regulations
have a significant effect on the manner in which we handle healthcare related data and communicate
with payors. We face potential administrative, civil, and criminal sanctions if we do not comply
with the existing or new laws and regulations. Imposition of these sanctions could have a material
adverse effect on our operations.
27
Enforcement of Healthcare Fraud and Abuse Laws. In recent years, the federal government has
made a policy decision to significantly increase the financial resources allocated to enforcing the
healthcare fraud and abuse laws. In addition, private insurers
and various state enforcement agencies have increased their level of scrutiny of healthcare
claims in an effort to identify and prosecute fraudulent and abusive practices in the healthcare
area. From time to time, we may be the subject of investigations or a party to additional
litigation which alleges violations of law. If any of those matters were successfully asserted
against us, there could be a material adverse effect on our business, financial position, results
of operations or prospects.
Anti-Kickback Statutes. As a provider of services under the Medicare and Medicaid programs,
we must comply with a provision of the federal Social Security Act, commonly known as the federal
anti-kickback statute. The federal anti-kickback statute prohibits the offer or receipt of any
bribe, kickback or rebate in return for the referral or arranging for the referral of patients,
products or services covered by federal healthcare programs. Federal healthcare programs have been
defined to include plans and programs that provide health benefits funded by the United States
Government, including Medicare, Medicaid and TRICARE (formerly known as the Civilian Health and
Medical Program of the Uniformed Services or CHAMPUS), among others. Some courts and the OIG
interpret the statute to cover any arrangement where even one purpose of the remuneration is to
influence referrals. Violations of the federal anti-kickback statute may result in civil and
criminal penalties and exclusion from participation in federal healthcare programs.
Due to the breadth of the federal anti-kickback statutes broad prohibition, there are a few
statutory exceptions that protect various common business transactions and arrangements from
prosecution. In addition, the OIG has published safe harbor regulations that outline other
arrangements that also are deemed protected from prosecution under the federal anti-kickback
statute, provided all applicable criteria are met. The failure of an activity to meet all of the
applicable safe harbor criteria does not necessarily mean that the particular arrangement violates
the federal anti-kickback law, but these arrangements will be subject to greater scrutiny by
enforcement agencies.
Some states have enacted statutes and regulations similar to the federal anti-kickback
statute, but which apply not only to the federal healthcare programs, but also to any payor source
of the patient. These state laws may contain exceptions and safe harbors that are different from
those of the federal law and that may vary from state to state. Additionally, a number of states
in which we operate have laws that prohibit fee-splitting arrangements between healthcare
providers, if such arrangements are designed to induce or encourage the referral of patients to a
particular provider. Possible sanctions for violations of these restrictions include exclusion
from state-funded healthcare programs, loss of licensure and civil and criminal penalties. Such
statutes vary from state to state, are often vague and often have been subject to only limited
court or regulatory agency interpretation.
Physician Self-Referral. Certain provisions of the Omnibus Budget Reconciliation Act of 1993
(Stark) prohibit healthcare providers such as us, subject to certain exceptions, from submitting
claims to the Medicare and Medicaid programs for designated health services if we have a financial
relationship with the physician making the referral for such services or with a member of such
physicians immediate family. The term designated health services includes several services
commonly performed or supplied by us, including DME and home health services. In addition,
financial relationship is broadly defined to include any ownership or investment interest or
compensation arrangement pursuant to which a physician receives remuneration from the provider at
issue. The prohibition of Stark applies regardless of the reasons for the financial relationship
and the referral; and therefore, unlike the federal anti-kickback statute, an intent to violate the
law is not required. Like the federal anti-kickback statute, Stark contains a number of statutory
and regulatory exceptions intended to protect certain types of transactions and business
arrangements from penalty. In order to qualify an arrangement under a Stark exception, compliance
with all of the exceptions requirements is necessary. Violations of Stark may result in loss of
Medicare and Medicaid reimbursement, civil penalties and exclusion from participation in the
Medicare and Medicaid programs.
In addition, a number of the states in which we operate have similar prohibitions against
physician self-referrals, which may not necessarily be limited to Medicare or Medicaid services and
may not include the same statutory and regulatory exceptions found in Stark.
False Claims. The federal False Claims Acts impose civil and criminal liability on
individuals or entities that submit false or fraudulent claims for payment to the government.
Violations of the federal civil False Claims Act may result in treble damages, civil monetary
penalties and exclusion from the Medicare, Medicaid, and other federally funded healthcare
programs. If certain criteria are satisfied, the federal civil False Claims Act allows a private
individual to bring a qui tam suit on behalf of the government and, if the case is successful, to
share in any recovery. Federal False Claims Act suits brought directly by the government or
private individuals against healthcare providers, like us, are increasingly common and are expected
to continue to increase.
28
The False Claims Corrections Act of 2007 introduced both in the House and the Senate and
approved by the House Committee on the Judiciary on July 16, 2008, proposes significant revisions
to the existing federal False Claims Act. Among other changes, the bill repeals the requirement
that false claims be presented to a government employee and clarifies under what circumstances a
government
employee may act as a qui tam relator under the False Claims Act. The bill extends the
statute of limitations period in federal False Claims Act cases to 10 years, but was recently
revised by the House Judiciary Committee to provide for an eight-year statute of limitations. The
False Claims Corrections Act would require, upon motion of the Attorney Generals Office, a court
to dismiss an action or claim if the allegations relating to all essential elements of liability of
the action or claim are based exclusively on the public disclosure of allegations or transactions
in specified federal hearings or reports or from the news media. Only the Attorney Generals
Office may move for this dismissal and thus, the defendant is precluded from making this argument.
The bill extends protection from retaliatory action to government contractors and agents, rather
than just covering government employees.
The federal government has used the federal False Claims Act to prosecute a wide variety of
alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare
programs. The government and a number of courts also have taken the position that claims presented
in violation of certain other statutes, including the federal anti-kickback statute or the Stark
Law, can be considered a violation of the federal False Claims Act, based on the theory that a
provider impliedly certifies compliance with all applicable laws, regulations, and other rules when
submitting claims for reimbursement.
A number of states have enacted false claims acts that are similar to the federal False Claims
Act. Even more states are expected to do so in the future because Section 6031 of the DRA amended
the federal law to encourage these types of changes in law at the state level. In addition, there
is a corresponding increase in state-initiated false claims enforcement efforts. Under the DRA, if
a state enacts a false claims act that is at least as stringent as the federal statute and that
also meets certain other requirements, the state will be eligible to receive a greater share of any
monetary recovery obtained pursuant to certain actions brought under the states false claims act.
Other Fraud and Abuse Laws. HIPAA created, in part, two new federal crimes: Healthcare
Fraud and False Statements Relating to Healthcare Matters. The Healthcare Fraud statute
prohibits executing a knowing and willful scheme or artifice to defraud any healthcare benefit
program. A violation of this statute is a felony and may result in fines and/or imprisonment. The
False Statements statute prohibits knowingly and willfully falsifying, concealing or covering up a
material fact by any trick, scheme or device or making any materially false, fictitious or
fraudulent statement in connection with the delivery of or payment for healthcare benefits, items
or services. A violation of this statute is a felony and may result in fines and/or imprisonment.
Certification
of Compliance Agreement. Pursuant to the merger agreement to acquire Coram, we
assumed Corams obligations. On August 22, 2007, Coram entered into a Certification of Compliance
Agreement with the OIG (Compliance Agreement) which obligates Coram to maintain a compliance
program to monitor, ensure compliance with federal healthcare program requirements and submit
timely reports to the government regarding the same. Violation of the terms of the Compliance
Agreement could result in the imposition of penalties and sanctions, including disqualification
from Medicare and other reimbursement programs.
Facility and Clinician Licensure. Various federal and state authorities and clinical practice
boards regulate the licensure of our facilities and clinical specialists working for us, either
directly as employees or on a per diem or contractual basis. Regulations and requirements vary
from state to state. Several states are currently contemplating the establishment or expansion of
facility licensure related to the home healthcare industry. We are committed to complying with all
applicable licensing requirements and maintain centralized functions to manage over 4,500 facility
licenses that are required to operate our business.
Healthcare Reform Legislation. Economic, political and regulatory influences are causing
fundamental changes in the healthcare industry in the United States. Various healthcare reform
proposals are formulated and proposed by the legislative and administrative branches of the federal
government on a regular basis. In addition, some of the states in which we operate periodically
consider various healthcare reform proposals. We anticipate that federal and state governments
will continue to review and assess alternative healthcare delivery systems and payment
methodologies and public debate of these issues will continue in the future. Changes in the law or
new interpretations of existing laws can have a substantial effect on permissible activities, the
relative costs associated with doing business in the healthcare industry and the amount of
reimbursement by governmental and other third-party payors. Due to uncertainties regarding the
ultimate features of reform initiatives and their enactment and implementation, we cannot predict
which, if any, of such reform proposals will be adopted, or when they may be adopted, or that any
such reforms will not have a material adverse effect on our results of operations, cash flow,
capital resources and liquidity.
29
Results of Operations
Three Months Ended June 30, 2008 and 2007
Net Revenues. Net revenues increased $139.3 million, or 35.5%, to $531.2 million in the three
months ended June 30, 2008 from $391.9 million in the three months ended June 30, 2007. The 35.5%
increase resulted from an increase in sales volume that primarily related to the growth in our home
infusion therapy service line due to the Coram acquisition. The revenue growth rate for 2008 was
impacted by incremental Medicare revenue reductions of $6.1 million due to reimbursement changes.
Had those reductions not been implemented, revenues for 2008 would have increased by 37.1%. The
Medicare reimbursement changes related to:
|
|
|
the reduction in the equipment rental period from 15 to 13 months for certain respiratory
equipment such as Continuous Positive Airway Pressure Units, Nebulizer Units, Hospital Beds and
Wheelchairs (regulation effective date of February 2007); |
|
|
|
|
changing the maximum rental period on certain equipment such as bi-level airway pressure
devices from an unlimited rental period to 13 months (regulation effective date of May
2007); |
|
|
|
|
transfer of equipment ownership from us to the patient at the end of the 13-month rental
period (regulation effective date of February 2007); and |
|
|
|
|
respiratory drug reimbursement reductions effective April 1, 2008. |
We expect to face continued pricing pressures from Medicare as well as from our managed care
customers as these payors seek to lower costs by obtaining more favorable pricing from providers
such as us. In addition to the pricing reductions, such changes could cause us to provide reduced
levels of certain products and services in the future, resulting in a corresponding reduction in
revenue. However, given our high volume of managed care business, we are well-positioned among our
competitors with respect to the Medicare Advantage plan expansion. See Government Regulation
above.
The following table sets forth a summary of net revenues by service line:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
(in thousands) |
|
2008 |
|
|
2007 |
|
|
Increase |
|
|
Change |
|
Home respiratory therapy |
|
$ |
273,135 |
|
|
$ |
267,325 |
|
|
$ |
5,810 |
|
|
|
2.2 |
% |
Home infusion therapy |
|
|
205,509 |
|
|
|
72,297 |
|
|
|
133,212 |
|
|
|
184.3 |
|
Home medical equipment/other |
|
|
52,604 |
|
|
|
52,307 |
|
|
|
297 |
|
|
|
0.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net revenues |
|
$ |
531,248 |
|
|
$ |
391,929 |
|
|
$ |
139,319 |
|
|
|
35.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Home Respiratory Therapy. Home respiratory therapy revenues are derived primarily from
the provision of oxygen systems, home ventilators, obstructive sleep apnea equipment, nebulizers,
respiratory medications and related services. Revenues from the respiratory therapy service line
increased by 2.2% in the three months ended June 30, 2008 compared to the same period in 2007. The
majority of the Medicare pricing reductions discussed above impacted the respiratory therapy line.
Such reductions were $5.8 million in the three months ended June 30, 2008. Adjusted for the Medicare reductions, respiratory revenues increased by 4.3% in the
three months ended June 30, 2008 compared to the same
period in 2007. The growth in revenue dollars
in the three months ended June 30, 2008 resulted primarily from an increase in revenue from oxygen
equipment rental revenue and an increase in the rental and sale of bi-level airway pressure devices
and related supplies. These increases were offset by a decrease in respiratory drug revenue,
primarily as a result of the changes in Medicare reimbursement in this area.
Home Infusion Therapy. The home infusion therapy service line involves the
administration of drugs or nutrients directly into the body intravenously through a needle or
catheter. Infusion therapy services also include administering enteral nutrients directly into the
gastrointestinal tract through a feeding tube. Home infusion therapy revenues increased by 184.3%
in the three months ended June 30, 2008. During this period, growth resulted from the Coram
acquisition that we completed in December 2007.
Home Medical Equipment/Other. Home medical equipment/other revenues are derived from
the provision of equipment to assist patients with ambulation, safety and general care in and
around the home. Home medical equipment/other revenues increased by 0.6% in the three months ended
June 30, 2008. In 2008, $0.3 million of the Medicare reimbursement reductions impacted this service
line. Excluding the impact of the Medicare reimbursement changes home medical equipment/other
revenue would have increased by 1.2% for the three months ended June 30, 2008.
30
Gross
Profit. The gross profit margin in the three months ended June 30, 2008 was 60.6%
compared to 65.7% in the three months ended June 30, 2007. The decrease in gross profit margin is
due to the acquisition of the Coram business, in December 2007, which has a lower profit margin
than our home respiratory therapy and home medical equipment service lines due to the nature of the
infusion business. This decrease was offset by improvement in the home respiratory therapy and home
medical equipment gross profit margin. The improvement in the home respiratory therapy and home
medical equipment services lines for the three months ended June 30, 2008 primarily resulted from
our ability to secure favorable pricing on the purchases of products and supplies, offset by
increased costs related to the write-off of the remaining net book value of rental equipment at the
time of transfer of equipment ownership from us to our patients.
Provision for Doubtful Accounts. The provision for doubtful accounts is based on managements
estimate of the net realizable value of accounts receivable after considering actual write-offs of
specific receivables. Accounts receivable estimated to be uncollectible are provided for by
computing a required reserve using estimated future cash receipts
based on historical cash receipts collections as a percentage of
revenue. Management may adjust for changes in billing practices, cash
collection protocols or practices, or changes in general economic
conditions, new markets or products. The provision for doubtful accounts, expressed as a
percentage of net revenues, was 1.0% and 2.8% in the three months ended June 30, 2008 and 2007,
respectively. The decrease in 2008 from the 2007 levels resulted primarily from an improvement in
the home infusion therapy service line provision for doubtful accounts due to the Coram acquisition
which has a lower percentage of doubtful accounts and a higher rate of collections of bad debts.
Additionally, the home respiratory therapy and home medical equipment service lines improved due to
our continued collection efforts and improvement in the aging of our accounts receivable.
Selling, Distribution and Administrative Expenses. Selling, distribution and administrative
expenses are comprised of expenses incurred in direct support of operations and those associated
with administrative functions. Expenses incurred by the operating locations include salaries and
other expenses in the following functional areas: selling, distribution, intake, reimbursement,
warehousing and repair. Many of these operating costs are directly variable with revenue growth
patterns. Some are also very sensitive to market-driven price fluctuations such as facility lease
and fuel costs. The administrative expenses include overhead costs incurred by the operating
locations and corporate support functions. These expenses do not fluctuate with revenue growth as
closely as do operating costs.
Selling, distribution and administrative expenses, expressed as percentages of revenues were
51.2% for the three months ended June 30, 2008 compared to 53.4% for the three months ended June
30, 2007. The home infusion therapy services line selling, distribution and administrative expenses
were 33.8% for the three months ended June 30, 2008 compared to 22.7% for the three months ended
June 30, 2007. The home respiratory therapy services line and the home medical equipment service
line selling, distribution and administrative were 62.1% for the three months ended June 30, 2008
compared to 60.3% at June 30, 2007.
Selling, distribution and administrative expenses increased by $62.5 million for the three
months ended June 30, 2008 over the corresponding period in 2007. Labor and related expenses
increased $41.2 million, of which $36.7 million was attributable to our home infusion therapy
services line primarily related to our acquisition of Coram in December 2007. Other operating costs
increased $21.3 million, of which $16.7 million was attributable to our home infusion therapy
services line primarily related to our acquisition of Coram. The other increases in labor and other
operating costs were primarily due to increases in delivery costs (primarily fuel and vehicle lease
costs), commissions, stock based compensation expense, initial expenses related to cost savings
program initiatives, costs incurred in support of enterprise wide information system project, and
expenses incurred related to the potential sale of the Company which resulted in the Merger
Agreement with Blackstone, offset by decreases due to changes in estimates in general and
professional liability insurance expense.
Amortization of Intangible Assets. Amortization of intangible assets increased $0.3 million,
or 48.6%, to $1.0 million in the three months ended June 30, 2008 from $0.7 million in the three
months ended June 30, 2007. The increase in amortization expense for the three months ended June
30, 2008, when compared to the corresponding period in 2007, resulted from amortization in 2008
related to intangibles identified as part of our acquisition of Coram in December 2007 offset by a
decrease in amortization on intangibles that have become fully amortized.
Interest Expense. Interest expense decreased $0.2 million, or 2.9%, to $5.5 million in the
three months ended June 30, 2008 from $5.7 million in the three months ended June 30, 2007. This
decrease is due to reductions in interest rates offset by the impact of the $359 million we
borrowed to purchase Coram in December 2007.
Interest Income. Interest income decreased $0.3 million, or 49.9%, to $0.4 million in the
three months ended June 30, 2008 from $0.7 million in the three months ended June 30, 2007.
31
Income
Tax Expense. Our effective tax rate was 39.8% for the three months ended June 30, 2008
compared with 38.7% for the three months ended June 30, 2007.
Our effective tax rate is based on expected income, statutory tax rates and tax planning
opportunities available to us in the various jurisdictions in which we operate. Significant
management estimates and judgments are required in determining our effective tax rate. We are
routinely under audit by federal, state or local authorities regarding the timing and amount of
deductions, allocation of income among various tax jurisdictions and compliance with federal, state
and local tax laws. Tax assessments related to these audits may not arise until several years after
tax returns have been filed. Although predicting the outcome of such tax assessments involves
uncertainty, we believe that the recorded tax liabilities appropriately reflect our potential
obligations under FASB Interpretation No. 48,
Accounting for uncertainty in income taxes
(FIN 48).
Six Months Ended June 30, 2008 and 2007
Net Revenues. Net revenues increased $276.5 million, or 35.3%, to $1,059.2 million in the six
months ended June 30, 2008 from $782.7 million in the six months ended June 30, 2007. The 35.3%
increase resulted from an increase in sales volume that primarily related to the growth in our home
infusion therapy service line due to the Coram acquisition. The revenue growth rate for 2008 was
impacted by incremental Medicare revenue reductions of $9.1 million due to reimbursement changes.
Had those reductions not gone into place, revenues for 2008 would have increased by 36.5%. The
Medicare reimbursement changes related to:
|
|
|
the reduction in the equipment rental period from 15 to 13 months for certain respiratory
equipment such as Continuous Positive Airway Pressure Units, Nebulizer Units, Hospital Beds and
Wheelchairs (regulation effective date of February 2007); |
|
|
|
|
changing the maximum rental period on certain equipment such as bi-level airway pressure
devices from an unlimited rental period to 13 months (regulation effective date of May
2007); |
|
|
|
|
transfer of equipment ownership from us to the patient at the end of the 13-month rental
period (regulation effective date of February 2007); and |
|
|
|
|
respiratory drug
reimbursement reductions effective April 1, 2008. |
We expect to continue to face pricing pressures from Medicare as well as from our managed care
customers as these payors seek to lower costs by obtaining more favorable pricing from providers
such as us. In addition to the pricing reductions, such changes could cause us to provide reduced
levels of certain products and services in the future, resulting in a corresponding reduction in
revenue. However, given our high volume of managed care business, we are well-positioned among our
competitors with respect to the Medicare Advantage plan expansion. See Government Regulation
above.
The following table sets forth a summary of net revenues by service line:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
(in thousands) |
|
2008 |
|
|
2007 |
|
|
Increase |
|
|
Change |
|
Home respiratory therapy |
|
$ |
549,583 |
|
|
$ |
537,086 |
|
|
$ |
12,497 |
|
|
|
2.3 |
% |
Home infusion therapy |
|
|
406,027 |
|
|
|
141,265 |
|
|
|
264,762 |
|
|
|
187.4 |
|
Home medical equipment/other |
|
|
103,616 |
|
|
|
104,357 |
|
|
|
(741 |
) |
|
|
(0.7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net revenues |
|
$ |
1,059,226 |
|
|
$ |
782,708 |
|
|
$ |
276,518 |
|
|
|
35.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Home Respiratory Therapy. Home respiratory therapy revenues are derived primarily from
the provision of oxygen systems, home ventilators, obstructive sleep apnea equipment, nebulizers,
respiratory medications and related services. Revenues from the respiratory therapy service line
increased by 2.3% in the six months ended June 30, 2008. The majority of the Medicare pricing
reductions discussed above impacted the respiratory therapy line. Such reductions were $8.2 million
in the six months ended June 30, 2008. Adjusted for the Medicare reductions, respiratory revenues
increased by 3.8% in the six months ended June 30, 2008. The growth in revenue dollars in the six
months ended June 30, 2008 resulted primarily from an increase in revenue from oxygen equipment
rental revenue and an increase in rental and sale of bi-level airway pressure devices and related
supplies. These increases were offset by a decrease in respiratory drug revenue, primarily as a
result of the changes in Medicare reimbursement in this area.
Home Infusion Therapy. The home infusion therapy service line involves the
administration of drugs or nutrients directly into the body intravenously through a needle or
catheter. Infusion therapy services also include administering enteral nutrients directly into the
gastrointestinal tract through a feeding tube. Home infusion therapy revenues increased by
187.4% in the six months ended June 30, 2008. During this period, growth resulted from the Coram
acquisition that we completed in December 2007.
32
Home Medical Equipment/Other. Home medical equipment/other revenues are derived from
the provision of equipment to assist patients with ambulation, safety and general care in and
around the home. Home medical equipment/other revenues decreased by 0.7% in the six months ended
June 30, 2008. In 2008, $0.9 million of the Medicare reimbursement reductions impacted this service
line. Excluding the impact of the Medicare reimbursement changes home medical equipment/other
revenue would have increased by 0.2% for the six months ended June 30, 2008.
Gross
Profit. The gross profit margin in the six months ended June 30, 2008 was 60.8% compared
to 65.6% in the six months ended June 30, 2007. The decrease in gross profit margin is due to the
acquisition of the Coram business, in December 2007, which has a lower profit margin than our home
respiratory therapy and home medical equipment service lines due to the nature of the infusion
business. This decrease was offset by improvement in the home respiratory therapy and home medical
equipment gross profit margin. The improvement in the home respiratory therapy and home medical
equipment services lines for the six months ended June 30, 2008 primarily resulted from our ability
to secure favorable pricing on the purchases of products and supplies, offset by increased costs
related to the write-off of the remaining net book value of rental equipment at the time of
transfer of equipment ownership from us to our patients.
Provision for Doubtful Accounts. The provision for doubtful accounts is based on managements
estimate of the net realizable value of accounts receivable after considering actual write-offs of
specific receivables. Accounts receivable estimated to be uncollectible are provided for by
applying specific percentages to each receivables aging category, which is determined by the number
of days the receivable is outstanding. The provision for doubtful accounts, expressed as a
percentage of net revenues, was 1.5% and 2.7% in the six months ended June 30, 2008 and 2007,
respectively. The decrease in 2008 from the 2007 levels resulted primarily from improvement in the
home infusion therapy service line provision for doubtful accounts due to the Coram acquisition
which has a lower percentage of doubtful accounts and significant collections of bad debts.
Additionally, the home respiratory therapy and home medical equipment service lines improved due to
our continued collection efforts and improvement in the aging of our accounts receivable.
Selling, Distribution and Administrative Expenses. Selling, distribution and administrative
expenses are comprised of expenses incurred in direct support of operations and those associated
with administrative functions. Expenses incurred by the operating locations include salaries and
other expenses in the following functional areas: selling, distribution, intake, reimbursement,
warehousing and repair. Many of these operating costs are directly variable with revenue growth
patterns. Some are also very sensitive to market-driven price fluctuations such as facility lease
and fuel costs. The administrative expenses include overhead costs incurred by the operating
locations and corporate support functions. These expenses do not fluctuate with revenue growth as
closely as do operating costs.
Selling, distribution and administrative expenses, expressed as percentages of revenues were
51.0% for the six months ended June 30, 2008 compared to 53.1% for the six months ended June 30,
2007. The home infusion therapy services line selling, distribution and administrative expenses
were 34.3% at June 30, 2008 compared to 22.8% at June 30, 2007. The home respiratory therapy
services line and the home medical equipment service line selling, distribution and administrative
were 61.4% at June 30, 2008 compared to 59.8% at June 30, 2007.
Selling, distribution and administrative expenses increased by $124.7 million for the six
months ended June 30, 2008 over the corresponding period in 2007. Labor and related expenses
increased $81.2 million, of which $73.9 million was in our home infusion therapy services line
primarily related to our acquisition of Coram in December 2007. Other operating costs increased
$43.5 million, of which $33.8 million was in our home infusion therapy services line primarily
related to our acquisition of Coram. The remaining increases in labor and other operating costs
were primarily due to increases in delivery costs (primarily fuel and vehicle lease costs),
commissions, stock based compensation expense, initial expenses related to cost savings program
initiatives and costs incurred in support of enterprise wide information system project and
expenses incurred related to the potential sale of the Company which resulted in the Merger
Agreement with Blackstone, offset by decreases due to changes in estimates in general and
professional liability insurance expense.
Amortization of Intangible Assets. Amortization of intangible assets increased $0.4 million,
or 24.7%, to $2.1 million in the six months ended June 30, 2008 from $1.7 million in the six months
ended June 30, 2007. The increase in amortization expense for the six months ended June 30, 2008,
when compared to the corresponding period in 2007, resulted from amortization in 2008 related to
intangibles identified as part of our acquisition of Coram in December 2007 offset by a
decrease in amortization on intangibles that have become fully amortized.
33
Interest Expense. Interest expense increased $1.8 million, or 15.2%, to $13.8 million in the
six months ended June 30, 2008 from $12.0 million in the six months ended June 30, 2007. This
increase is due to the impact of the $359 million we borrowed to purchase Coram in December 2007,
partially offset by reductions in debt outstanding based upon repayments and lower interest rates.
Interest
Income. Interest income decreased $0.3 million, or 28.5%, to $0.9 million in the six
months ended June 30, 2008 from $1.2 million in the six months ended June 30, 2007.
Income Tax Expense. Our effective tax rate was 39.8% for the six months ended June 30, 2008
compared with 37.9% for the six months ended June 30, 2007.
Our effective tax rate is based on expected income, statutory tax rates and tax planning
opportunities available to us in the various jurisdictions in which we operate. Significant
management estimates and judgments are required in determining our effective tax rate. We are
routinely under audit by federal, state or local authorities regarding the timing and amount of
deductions, allocation of income among various tax jurisdictions and compliance with federal, state
and local tax laws. Tax assessments related to these audits may not arise until several years after
tax returns have been filed. Although predicting the outcome of such tax assessments involves
uncertainty, we believe that the recorded tax liabilities appropriately reflect our potential
obligations under FIN 48.
Liquidity and Capital Resources
Our principal source of liquidity is operating cash flow, which is supplemented by a $500
million revolving credit facility. In recent years, we have generated operating cash flows in
excess of operating needs, which has afforded us the ability to pursue acquisitions and fund
patient service equipment purchases to support revenue growth. We believe that our operating cash
flows will continue to be sufficient to fund our operations and growth strategies.
On September 1, 2008 holders of our 3 3/8% convertible senior notes may require us to redeem
some or all of the notes. The principal amount of the convertible senior notes is currently $250
million. In addition, if we are required to redeem all of the principal amount it would trigger tax
payments of approximately $30 million. On June 18, 2008, we entered into a $280 million credit
facility pursuant to the Credit Agreement. On September 2, 2008
proceeds of the new credit facility were used to fund repurchases of
our 3 3/8% Convertible Senior Notes due 2033 and will be used to pay the tax
liabilities related thereto. The loans under the credit facility bear interest at a rate of eleven
per cent (11%) per year with a maturity date of March 1, 2009. In addition, we paid usual and
customary bank fees in connection with entering into the Credit Agreement. The Credit Agreement
includes restrictions on additional indebtedness, business operations, liens, transfers and sales
of assets, and transactions with affiliates. The Credit Agreement also contains customary events of
default which would permit the lenders to accelerate payments under the Credit Agreement if not
cured within applicable grace periods, including the failure to make timely payments under the
Credit Agreement and the failure to follow certain covenants. As of June 30, 2008, the Company
was in compliance with all covenants, but, due to the non-timely filing of
the Companys quarterly report on Form 10-Q for the period
ended June 30, 2008,
the Company would have been in default of the reporting covenants
under the Credit Agreement on August 15, 2008. However, the
Companys lenders executed a waiver on August 14, 2008, which extended the filing requirement
from 45 days to 90 days following the end of the quarter.
Upon the
filing of this quarterly report on Form 10-Q for the
period ended June 30, 2008, the Company will have remedied the
non-compliance with reporting requirements under its Credit
Agreement. On
September 2, 2008, we repurchased $249.8 million in
aggregate principal of the senior notes, representing approximately
99.91% of the outstanding principal amount. $0.2 million of
principal of the senior notes remains outstanding.
We have initiated a project to implement a new enterprise-wide information system. The overall
objective of the project is to deliver the necessary technology and automation across the
organization to enable improvements in service, productivity and access to information. Development
on certain modules commenced in 2006 and continued in 2007 and 2008. The overall project plan is
being designed and developed and is expected to be implemented over several years.
In the six months ended June 30, 2008 and 2007, our free cash flow was $61.1 million and $75.8
million, respectively. Free cash flow is defined as cash provided by operating activities less
purchases of patient services equipment and property, equipment and improvements, exclusive of
effects of acquisitions. It is presented as a supplemental performance measure and is not intended
as an alternative to any other cash flow measure calculated in accordance with generally accepted
accounting principles. Further, free cash flow may not be comparable to similarly titled measures
used by other companies. A table reconciling free cash flow to net cash provided by operating
activities is presented below.
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
June 30, |
|
(dollars in thousands) |
|
2008 |
|
|
2007 |
|
Reconciliation Free Cash Flow: |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
$ |
157,428 |
|
|
$ |
131,610 |
|
Less: Purchases of patient service equipment and property, equipment and improvements |
|
|
(96,301 |
) |
|
|
(55,811 |
) |
|
|
|
|
|
|
|
Free cash flow |
|
$ |
61,127 |
|
|
$ |
75,799 |
|
|
|
|
|
|
|
|
34
Cash Flow. The following table presents selected data from our consolidated statement of cash
flows:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
(in thousands) |
|
2008 |
|
|
2007 |
|
Net cash provided by operating activities |
|
$ |
157,428 |
|
|
$ |
131,610 |
|
Net cash used in investing activities |
|
|
(99,284 |
) |
|
|
(55,759 |
) |
Net cash used in financing activities |
|
|
(63,534 |
) |
|
|
(62,025 |
) |
|
|
|
|
|
|
|
Net (decrease) increase in cash and equivalents |
|
|
(5,390 |
) |
|
|
13,826 |
|
Cash and equivalents at beginning of period |
|
|
28,451 |
|
|
|
14,657 |
|
|
|
|
|
|
|
|
Cash and equivalents at end of period |
|
$ |
23,061 |
|
|
$ |
28,483 |
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2008 and 2007
Net
cash provided by operations in the first half of 2008 was $157.4 million compared to
$131.6 million in the first half of 2007, an increase of $25.8 million. The increase in net cash
provided by operations resulted from a $44.8 million increase in income before non-cash items to
$179.8 million in 2008 from $135.0 million in 2007, offset by a $19.0 million increase in the cash
used related to the change in operating assets and liabilities to a $22.4 million use of cash in
2008 from a $3.4 million use of cash in 2007.
The $19.4 million increase in cash used by the change in operating assets and liabilities
consisted primarily of the following:
|
|
|
$4.5 million increase in cash used by the change in accrued payroll and related taxes and
benefits, to a $5.3 million use of cash in the six months ended June 30, 2008 from a $0.8
million use of cash in the six months ended June 30, 2007. The increase was primarily due to
an additional accrual day in 2008, an increase in accrued vacation and the Coram
acquisition; |
|
|
|
|
$8.9 million increase in cash used by accrued expenses to a $10.1 million use of cash in
the six months ended June 30, 2008 from a $1.2 million use of cash in the six months ended
June 30, 2007. The increase was primarily due to $4.5 million in accrued incentive
compensation and $5.0 million related to expenses from our Coram acquisition and a pay-down
of an installment purchase; and |
|
|
|
|
$17.3 million increase in cash used by income taxes payable to a $9.3 million use of cash
in the six months ended June 30, 2008 from a $8.0 million provision of cash in the six
months ended June 30, 2007. The increase in cash used primarily relates to 2008 reductions
in unrecognized tax benefits under FIN 48 and a lower amount of 2008 current tax liabilities
due to utilization of Corams tax net operating losses. |
Offset by:
|
|
|
$4.9 million decrease in cash used in accounts receivable, to a $16.1 million use of cash
in the six months ended June 30, 2008 from a $21.0 million use of cash in the six months
ended June 30, 2007. This decrease in use of cash was primarily due to a net increase in
accounts receivable primarily related to Coram; |
|
|
|
|
$2.4 million increase in cash provided by prepaid expenses and other current assets to a
$7.1 million provision of cash in the six months ended June 30, 2008 from a $4.7 million
provision of cash in the six months ended June 30, 2007. The increase was primarily due to
an increase in the prepaid infusion therapy inventory of $6.5 million from the prior year,
offset by a $3.6 million decrease in prepaid insurance and a $0.8 million decrease in other
prepaids; and |
|
|
|
|
$4.2 million increase in cash provided by accounts payable to a $7.8 million provision of
cash in the six months ended June 30, 2008 from a $3.6 million provision of cash in the six
months ended June 30, 2007. The increase was primarily due to a $7.0 million increase in
trade accounts payable offset by a $1.6 million change in book cash overdraft. |
Investing
activities used $99.3 million in the first half of 2008 compared to $55.8 million in
the first half of 2007. The primary use of funds in the first half of
2008 was $96.3 million to
purchase patient service equipment and property, equipment and
improvements; $64.0 million related
to patient service equipment and $32.3 million related to property, plant and equipment, primarily
due to additions to our information systems hardware and software. The primary use of funds in the
first half of 2007 was $55.8 million to purchase patient service equipment and property, equipment
and improvements. Of this $55.8 million, $38.8 million related to patient service equipment and
$17.0 million related to property, plant and equipment.
35
Net cash used in financing activities in the first half of 2008 was $63.5 million compared to
net cash used in financing of $62.0 million in the first half of 2007. In 2008, net cash provided
by financing activities reflected our borrowing of $7.6 million under the revolving credit
facility, offset by $67.6 million of payments we made to reduce outstanding debt. Net cash used in
financing activities in 2007 reflected our repayment of $80.0 million under the revolving credit
facility, partially offset by issuances of common stock of $16.6 million in connection with the
exercises of stock options and release of equity awards.
Accounts
Receivable. Accounts receivable before allowance for doubtful
accounts were $329.2
million at June 30, 2008 and $332.0 million at December 31, 2007. Days sales outstanding (calculated as of
each period-end by dividing accounts receivable, less allowance for doubtful accounts, by the
90-day rolling average of net revenues) were 51 days at
June 30, 2008 and 48 days at December 31, 2007.
Accounts aged in excess of 180 days expressed as percentages of total receivables for certain
payor categories are as follows:
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
|
|
2008 |
|
|
2007 |
|
Medicare |
|
|
13.2 |
% |
|
|
23.9 |
% |
Medicaid |
|
|
20.4 |
% |
|
|
23.2 |
% |
Self pay |
|
|
44.7 |
% |
|
|
40.7 |
% |
Managed care/other |
|
|
18.5 |
% |
|
|
19.3 |
% |
Total |
|
|
18.2 |
% |
|
|
21.1 |
% |
Unbilled Receivables. Included in accounts receivable are earned but unbilled receivables of
$51.1 million and $48.3 million at June 30, 2008 and December 31, 2007, respectively. Delays,
ranging from a day up to several weeks, between the date of service and billing can occur due to
delays in obtaining certain required payor-specific documentation from internal and external
sources. Earned but unbilled receivables are aged from date of service and are considered in our
analysis of historical performance and collectibility.
Inventories and Patient Service Equipment. Inventories consist primarily of pharmaceuticals
and disposable products used in conjunction with patient service equipment. Patient service
equipment consists of respiratory and home medical equipment that is provided to in-home patients
for the course of their care plan, normally on a rental basis, and subsequently returned to us for
redistribution after cleaning and maintenance is performed.
The branch locations serve as the primary point from which inventories and patient service
equipment are delivered to patients. Certain products and services, such as infusion therapy and
respiratory medications, bypass the branches and are provided directly to patients from pharmacies
or other central locations. The branches are supplied with inventory and equipment from central
warehouses that service specific areas of the country. Such warehouses are also responsible for
repairs and scheduled maintenance of patient service equipment, which adds to the frequent movement
of equipment between locations. Further, the majority of our patient service equipment is located
in patients homes. While utilization varies widely between equipment types, on the average,
approximately 86.1% of equipment is on rent at any given time. Inherent in this asset flow is the
fact that losses will occur. Depending on the product type, we perform physical inventories on an
annual or quarterly basis. Inventory and patient service equipment balances in the financial
records are adjusted to reflect the results of these physical inventories. Inventory and patient
service equipment losses for the three months ended June 30, 2008 and 2007 were $1,023,000 and
$821,000, respectively.
Long-term Debt. At June 30, 2008, borrowings under our revolving credit facility were $364.0
million; outstanding letters of credit totaled $7.8 million; credit available under the revolving
facility was $128.2 million; and we were in compliance with all covenants required by the 2004
Credit Agreement. The effective interest rate at June 30, 2008, after consideration of the effect
of the swap agreement described under Hedging Activities below was 3.2%.
Liquidity Credit Facility: On
June 18, 2008, the Company entered into a $280 million credit
facility pursuant to the Credit Agreement. Proceeds of the new credit facility
were used to fund potential repurchases of the Company’s 3 3/8%
Convertible Senior Notes due 2033 and will be used to pay certain tax liabilities related
thereto. The loans under the credit facility bear interest at a rate of eleven
per cent (11%) per year with a maturity date of March 1, 2009. In
addition, the Company paid usual and customary bank fees in connection with
entering into the Credit Agreement. The Credit Agreement includes restrictions
on the Company regarding additional indebtedness, business operations, liens,
transfers and sales of assets, and transactions with affiliates. The Credit
Agreement also contains customary events of default which would permit the
lenders to accelerate payments under the Credit Agreement if not cured within
applicable grace periods, including the failure to make timely payments under
the Credit Agreement and the failure to follow certain covenants. As of
June 30, 2008, the Company was in compliance with all covenants, however,
due to the non-timely filing of the Company’s Form 10-Q, the Company
would have been in default of the reporting covenants under the Credit
Agreement on August 15, 2008. However, the Company’s lenders executed
a waiver on August 14,
2008, which extended the filing requirement from 45 days to 90 days
following the end of the quarter.
Convertible Senior Notes. At June 30, 2008, the fair value of the $250 million in convertible
senior notes was $249 million, as determined by reference to quoted market prices.
On
September 2, 2008, the Company repurchased $249.8 million in aggregate
principal of its senior notes representing approximately 99.91% of the
outstanding principal amount. $0.2 million in aggregate principal amount of the
senior notes remains outstanding.
Hedging Activities. We are exposed to interest rate fluctuations on our underlying variable
rate long-term debt. Our policy for managing interest rate risk is to evaluate and monitor all
available relevant information, including but not limited to, the structure of our interest-bearing
assets and liabilities, historical interest rate trends and interest rate forecasts published by
major financial institutions. The tools we may utilize to moderate our exposure to fluctuations in
the relevant interest rate indices include, but are not limited to: (1) strategic determination of
repricing periods and related principal amounts, and (2) derivative financial instruments such as
interest rate swap agreements, caps or collars. We do not use derivative financial instruments for
trading or other speculative purposes.
36
At June 30, 2008, we had one interest rate swap agreement in effect which will expire in
January 2009 and has a notional amount of $25 million with a fixed rate of 4.44%.
We account for our swap agreement under SFAS No. 133, Accounting for Derivative Instruments
and Hedging Activities. The difference between the interest received and interest paid is
reflected as an adjustment to interest expense. We received a net settlement amount of $18,000 and
$58,000 related to the three-month period ended June 30, 2008 and 2007, respectively, and $69,000
and $117,000 for the six months ended June 30, 2008 and 2007, respectively. The aggregate fair
value of the swap agreement was a liability of $198,000 and $105,000 at June 30, 2008 and December
31, 2007, respectively, and is reflected in the accompanying condensed consolidated balance sheets
in other accrued liabilities. Our interest rate swap agreement is valued using observable market
based inputs and therefore is classified within Level 2. Unrealized gains and losses on the fair
value of the swap agreement are reflected in net income, as the transaction does not qualify for
hedge accounting. Our exposure to credit loss under the swap agreement is limited to the interest
rate spread in the event of counterparty nonperformance. We do not anticipate losses due to
counterparty nonperformance as its counterparties to the swap agreement are nationally recognized
financial institutions with strong credit ratings.
Treasury Stock. In the first six months of 2008, 57,191 shares of employee share-based awards,
valued at $1,263,000 were tendered back to us to satisfy the related purchase and tax obligations.
Business Combinations. Business combinations are accounted for as purchases and the results of
operations of the acquired companies are included in the accompanying condensed consolidated income
statements from the dates of acquisition. Covenants not to compete are being amortized over the
life of the respective agreements. Tradenames are being amortized over the period of their expected
benefit.
During the six months ended June 30, 2008 and 2007, we did not make any acquisitions. Cash
paid for acquisitions, which includes amounts deferred from prior periods, totaled $3.0 million.
Contractual Cash Obligations.
There were no material changes from December 31, 2007 reported amounts.
Off-Balance Sheet Arrangements
We are not a party to off-balance sheet arrangements as defined by the Securities and Exchange
Commission. However, from time to time we enter into certain types of contracts that contingently
require us to indemnify parties against third-party claims. The contracts primarily relate to: (i)
certain asset purchase agreements, under which we may provide customary indemnification to the
seller of the business being acquired; (ii) certain real estate leases, under which we may be
required to indemnify property owners for environmental and other liabilities, and other claims
arising from our use of the applicable premises; and (iii) certain agreements with our officers,
directors and employees, under which we may be required to indemnify such persons for liabilities
arising out of their relationship with us.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to interest rate fluctuations on our underlying variable rate long-term debt.
We utilize interest rate swap agreements to moderate such exposure. We do not use derivative
financial instruments for trading or other speculative purposes.
At June 30, 2008, our revolving credit facility borrowings totaled $364.0 million. The 2004
Credit Agreement, which governs the revolver, provides interest rate options based on the following
indices: Federal Funds Rate, the Bank of America prime rate or the London Interbank Offered Rate
(LIBOR). All such interest rate options are subject to the application of an interest margin as
specified in the bank credit agreement. At June 30, 2008 all of our outstanding revolving debt was
tied to LIBOR.
During the first six months of 2008, we had one interest rate swap agreement in effect to fix
our LIBOR-based variable rate debt. The agreement became effective in January 2006 for a three-year
term, and has a notional amount of $25 million that fixes an equivalent amount of our variable rate
long-term debt at 4.44%.
37
Based on the revolving debt outstanding and the swap agreement in place at June 30, 2008, a
100 basis point change in the applicable interest rates would increase or decrease our annual cash
flow and pretax earnings by approximately $3,390,000. See Managements Discussion and Analysis of
Financial Condition and Results of Operations Long-term Debt Hedging Activities.
ITEM
4. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
In connection with the preparation
of this Quarterly Report on Form 10-Q and in accordance with Exchange Act Rules 13a-15 and 15d-15, we carried
out an evaluation, under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of the end of
the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that the effectiveness of our disclosure controls and procedures were not effective as of June 30, 2008
because of the material weakness in our internal control over
financial reporting discussed below. A material weakness is a deficiency, or a
combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility
that a material misstatement of the companys annual or interim financial statements will not be prevented or detected
on a timely basis. Management identified the following material
weakness:
Managements
estimate of the reserve for uncollectible accounts receivable. We did not effectively design and perform control
activities to prevent or detect material misstatements that might exist in our reserve for uncollectible accounts receivable.
Specifically, we did not perform an analysis with a sufficient level of detail to support managements estimate of the reserve
for uncollectible accounts receivable.
Notwithstanding the material weakness described
above, based upon the work performed by the Company during August and September of 2008, including our review of accounts
receivable reserves as of June 30, 2008 we have concluded that there were no material adjustments required to the reported accounts receivable reserve amounts, and that our unaudited consolidated financial statements for the periods covered
by and included in this Form 10-Q are fairly stated in all material respects in accordance with generally accepted
accounting principles in the United States of America.
(b) Changes
in Internal Control Over Financial Reporting
During
the three month period ended June 30, 2008 there have been no changes to
our internal control over financial reporting that have materially
affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
(c) Future
Remediation Plan for Material Weakness
During
September 2008, we completed
the design and implementation of control activities that we believe will prevent or detect material misstatements that
might exist in our reserve for uncollectible accounts receivable. Specifically, we have developed a process to assess
our historical cash receipts experience and consider other relevant factors to support managements estimate for uncollectible
accounts receivable. While management believes that these steps are appropriate to remediate the material weakness in our
internal control over financial reporting, management cannot conclude that remediation is complete until such controls
operate for a sufficient period of time and are tested further.
Following testing of operating effectiveness, we believe our
remediation will be complete in the fourth quarter of 2008.
PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are the defendant in a purported California class action lawsuit asserting blanket claims
of liability under various California employee protection statutes and regulations relating to
payment of regular and overtime wages, the timeliness of such payments, the maintenance and
provision of access to required payroll records, and the provision of meal and rest periods. The
original claim was filed by Jesus Venegas on February 21, 2006 in the California Superior Court for
the County of San Francisco (Case No. CGC 06 449669). The complaint, as amended, seeks
compensatory damages in an unspecified amount as well as other relief on behalf of a purported
class consisting of substantially all of our delivery drivers in the State of California. The
Company has answered the complaint denying all material allegations and asserting a number of
affirmative defenses. We have successfully pursued motions for summary adjudication eliminating
certain tort based claims and claims for unjust enrichment and declaratory relief. Based on the
investigation of the allegations made to date, we believe there are meritorious defenses to the
remaining claims and intend to continue a vigorous defense of the lawsuit. The Court has not
established a trial date and has indicated that the issue of whether the case may be certified as a
class action is likely to be determined at a hearing which it expects to hold in early 2009. Until
a final decision is made with respect to the plaintiffs class action allegations, no assurances
can be given that the ultimate disposition of this case will not have a material adverse effect on
our financial condition or results of operations.
We have also been served with two complaints seeking to enjoin the proposed Merger. The first
complaint was filed on June 24, 2008 by Alaska Ironworkers Pension Trust, On Behalf of Itself and
All Others Similarly Situated, in the Superior Court of the State of California, County of Orange,
Case No. 30-2008-00078710. The complaint names the Company and its directors as defendants, and
asserts a single cause of action for breach of fiduciary duty and aiding and abetting against all
defendants. The complaint seeks certification of a class of all common stockholders of the Company
who are being and will be harmed by defendants alleged actions; a declaration that the proposed
transaction is in breach of defendants fiduciary duties, and, therefore, unlawful and
unenforceable; an order enjoining defendants and others from consummating the proposed transaction;
an order directing the individual defendants to exercise their fiduciary duties to obtain a
transaction in the best interests of the Companys stockholders; rescission of the proposed
transaction to the extent already implemented; recovery of costs of suit, including attorneys
fees; and other relief.
The second complaint was filed on July 2, 2008 by Bruce Ellis, On Behalf of Himself and All
Others Similarly Situated, in the Superior Court of the State of California, County of Orange, Case
No. 30-2008-00081027. The complaint names the Company, the Companys directors, and Blackstone
Group LP as defendants, and asserts two (2) causes of action: (1) breach of fiduciary duty against
the individual defendants, and (2) aiding and abetting the individual defendants breach of
fiduciary duty against Blackstone Group LP. The complaint seeks certification of a class of all
common stockholders of the Company who are being and will be harmed by defendants alleged actions;
a declaration that the proposed transaction is in breach of defendants fiduciary duties, and,
therefore, unlawful and unenforceable; an order enjoining defendants and others from consummating
the proposed transaction; an order enjoining the defendants from holding a shareholder vote on the
proposed transaction until curative disclosures are made; an order directing the individual
defendants to exercise their fiduciary duties to obtain a transaction which is in the best
interests of the Companys stockholders; rescission of the proposed transaction to the extent
already implemented; imposition of a constructive trust,
in favor of plaintiff, upon any benefits improperly received by defendants; recovery of costs
of suit, including attorneys fees; and other relief.
38
On July 15, 2008, the Court issued an Order on Consolidation of Related Actions and
Appointment of Lead Counsel, where the Court, among other things, consolidated the above actions,
as well as other current or future actions arising out of the same set of facts that are filed in
or transferred to the Court, into a single action, titled In re Apria Healthcare Group Inc.
Shareholder Litigation, Lead Case No. 30-2008-00078710. Coughlin, Stoia, Geller, Rudman & Robbins
LLP was appointed as lead counsel for plaintiffs in the consolidated action. The Court further
ordered plaintiffs to file a consolidated complaint within 30 days of the July 24, 2008 filing with
the SEC of the Companys preliminary proxy statement on Schedule 14A. The parties have stipulated to
extend this deadline to September 22, 2008, and plaintiffs have not filed a
consolidated complaint as of the date of the filing of this Form 10-Q. Pursuant to the July 15, 2008
order, the consolidated complaint will supersede all complaints filed in any consolidated action,
and defendants shall respond to the consolidated complaint pursuant to a briefing schedule to be
agreed upon by the parties and approved by the Court. Also pursuant to the order, defendants are
not required to, and have not, responded to the foregoing complaints.
We are also engaged in the defense of certain claims and lawsuits
arising out of the ordinary course and conduct of our business, the
outcomes of which are not determinable at this time. Insurance
policies covering such potential losses, where such coverage is cost
effective, are maintained. In the opinion of management, any
liability that might be incurred upon the resolution of these claims
and lawsuits will not, in aggregate, have a material adverse effect
on our financial condition or results of operations.
ITEM 1A. RISK FACTORS
The risk factors presented in our Annual Report on Form 10-K/A for the year ended December 31,
2007, as filed with the Securities and Exchange Commission on February 29, 2008, are incorporated
herein by reference. With the exception of the risk factor amended and restated below, there have
been no changes from those risk factors during the period covered by this report.
The failure to complete the pending sale of the Company could have a materially adverse
impact.
On June 18, 2008, we entered into a Merger Agreement, by and among Apria, Buyer and Merger
Sub. Buyer is controlled by a private investment fund affiliated with Blackstone. Consummation of
the Merger with Merger Sub is subject to the terms and conditions of the Merger Agreement,
including, but not limited to the approval of Aprias stockholders. There can be no assurance that
Aprias stockholders will approve the Merger Agreement or that the other conditions to the
completion of the Merger will be satisfied. If the Merger is not completed for any reason, the
price of Aprias common stock will likely decline to the extent that the market price of the common
stock reflects market assumptions that the Merger will be completed. Additionally, Apria is
subject to additional risks in connection with the Merger, including: (1) the occurrence of an
event, change or circumstance that could give rise to the payment of a termination fee to Buyer
pursuant to the terms of the Merger Agreement, (2) the outcome of any legal proceedings that have
been or may be instituted against Apria and others relating to the transactions contemplated by the
Merger Agreement, (3) the failure of the Merger to close for any reason or the failure of Buyer to
obtain the necessary debt financing set forth in the commitment letters provided to Apria in
connection with the Merger, (4) the restrictions imposed on Aprias business, properties and
operations pursuant to the affirmative and negative covenants set forth in the Merger Agreement and
the potential impact of such covenants on Aprias business, (5) the risk that the proposed
transaction will divert managements attention resulting in a potential disruption of the Companys
current business plan, (6) potential difficulties in employee retention arising from the Merger,
(7) the effect of the announcement of the Merger on Aprias business relationships, operating
results and business generally and (8) the amount of fees, expenses and charges incurred by the
Company in connection with the Merger.
39
Medicare/Medicaid Reimbursement Rates Continued Reductions in Medicare and Medicaid
Reimbursement Rates Could Have a Material Adverse Effect on Our Results of Operations and Financial
Condition.
There are ongoing legislative and regulatory efforts to reduce or otherwise adversely affect
Medicare reimbursement rates for products and services we provide. For example, the regulations
implementing the mandates under the MMA reduced the reimbursement for a number of products and
services we provide and established a competitive bidding program for certain durable medical
equipment under Medicare Part B. The Medicare DMEPOS competitive bidding program is intended to
further reduce reimbursement for certain products as well as decrease the number of companies
permitted to serve Medicare beneficiaries. Although the competitive bidding program began (Round
1) in 10 of the CBAs on July 1, 2008, MIPPA, which was enacted on July 15, 2008, terminated the
existing agreements with Round 1 winning contract suppliers and required that Round 1 of the DMEPOS
competitive bidding program be delayed until 2009, with CMS also required to make certain changes
to the competitive bidding process. At this time, it is unclear what specific changes CMS will
make to the bidding process and the competitive bidding program as a whole to address the concerns
that led to the passage of MIPPA, and we cannot quantify what negative impact, if any, the revised
program will have upon our revenue or operations once the program is reinitiated.
In order to
ensure that the delay would achieve the same level of savings projected for the
DMEPOS competitive bidding program, Congress adopted a nationwide 9.5% payment reduction in the
DMEPOS fee schedule for those product categories included in Round 1, effective January 1, 2009.
Those DMEPOS items that were not subject to Round 1 competitive bidding will receive a full CPI
update each year from 2009 through 2013. In 2014 these items will receive the CPI update plus 2%.
Further, the DRA resulted in reduced reimbursement rates for certain durable medical
equipment, including the home oxygen equipment and services we provide, a reduced period for rental
revenue, and potential increased costs to us associated with replacement of certain patient-owned
equipment. There have been proposals by the President and Congress to further reduce the maximum
capped rental period for oxygen below the 36-month level mandated by the DRA to 13 and 18 months,
respectively, and/or to reduce payment rates for oxygen equipment. While these proposals have not
been enacted, similar proposals may be raised in the future.
In addition to these activities, certain other proposed legislative and regulatory activities
may affect reimbursement policies and rates for other items and services we provide. These enacted
and proposed changes, including actual or pending proposed reductions in Medicare reimbursement
rates or rental periods for our products and services, could have a material adverse effect on our
results of operations, cash flow, capital resources and liquidity.
There are ongoing state and federal legislative and regulatory efforts to reduce or otherwise
adversely affect Medicaid reimbursement rates for products and services we provide. For a number
of years, some states have adopted alternative pricing methodologies for certain drugs, biologicals
and home medical equipment reimbursed under the Medicaid program. In a number of states, the
changes reduced the level of reimbursement we received for these items without a corresponding
offset or increase to compensate for the service costs we incurred. In several of those states, we
elected to stop accepting new Medicaid patient referrals for the affected drugs and biologicals.
In light of continuing budget pressure, states may continue to consider new or other reductions in
Medicaid reimbursement for drugs, biologicals, and other durable medical equipment and affiliated
services. In addition, changes to the federal regulations pertaining to prescription drug pricing
may also impact the Medicaid reimbursement available to us.
We cannot estimate the ultimate impact of all legislated and contemplated Medicare and
Medicaid reimbursement changes or provide assurance to investors that additional reimbursement
reductions will not be made or will not have an adverse effect on our results of operations, cash
flow, capital resources and liquidity.
For further
information, see Managements Discussion and Analysis of Financial Condition and
Results of Operations Government Regulation.
Government Regulation; Healthcare Reform Non-Compliance with Laws and Regulations Applicable
to Our Business and Future Changes in Those Laws and Regulations Could Have a Material Adverse
Effect on Us.
We are subject to stringent laws and regulations at both the federal and state levels,
requiring compliance with burdensome and complex billing, substantiation and record-keeping
requirements. Financial relationships between us and physicians and other referral sources are also
subject to strict limitations. In addition, strict licensure, accreditation and safety requirements
apply to the provision of services, pharmaceuticals and medical equipment. Violations of these laws
and regulations could subject us to severe fines, facility
shutdowns and possible exclusion from participation in federal healthcare programs such as
Medicare and Medicaid. In addition, from time to time, we may be the subject of investigations or
a party to additional litigation which alleges violations of law. If any of those matters were
successfully asserted against us, there could be a material adverse effect on our business,
financial position, results of operations or prospects.
40
Government officials and the public will continue to debate healthcare reform. Potential new
federal or state public policy changes to cover the uninsured could ultimately also affect payment
rates to providers or initiate new provider fees or taxes. Changes in public policy, healthcare
law, new interpretations of existing laws, or changes in payment methodology may have a significant
effect on our business, results of operations, cash flow, capital resources and liquidity.
Certification of Compliance Agreement Non-Compliance with Requirements of Agreement Could
Result in the Imposition of Significant Penalties and Sanctions.
As part of our acquisition of Coram, we assumed Corams obligations including those imposed on
Coram as part of its Certification of Compliance Agreement with the Health and Human
Services Office of Inspector General,
which requires Coram to maintain a compliance program,
monitor and ensure compliance with federal healthcare program requirements and submit timely
reports to the government regarding the same. Violation of the terms of the Compliance Agreement
could result in the imposition of significant penalties and sanctions, including disqualification
from Medicare and other reimbursement programs.
ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
(a) |
|
The Annual Meeting of Stockholders of the Company on May 9, 2008. |
|
|
(b) |
|
Directors elected or reelected at the Annual Meeting for a term of one year: |
|
|
|
|
Vicente Anido, Jr.
Terry P. Bayer
I.T. Corley
David L. Goldsmith
Lawrence M. Higby
Richard H. Koppes
Philip R. Lochner, Jr.
Norman C. Payson, M.D.
Mahvash Yazdi |
41
|
(c) |
|
Matters Voted Upon at Annual Meeting: |
|
|
|
|
As of May 9, 2008, the Companys Board of Directors consisted of nine
members. The results of the stockholder voting were as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WITHHOLD/ |
|
|
BROKER |
|
|
|
FOR |
|
|
ABSTENTIONS |
|
|
NON-VOTES |
|
Vicente Anido, Jr. |
|
|
40,556,117 |
|
|
|
450,721 |
|
|
|
|
|
Terry P. Bayer |
|
|
40,571,479 |
|
|
|
435,359 |
|
|
|
|
|
I.T. Corley |
|
|
38,981,473 |
|
|
|
2,025,365 |
|
|
|
|
|
David L. Goldsmith |
|
|
38,833,530 |
|
|
|
2,173,308 |
|
|
|
|
|
Lawrence M. Higby |
|
|
40,571,490 |
|
|
|
435,348 |
|
|
|
|
|
Richard H. Koppes |
|
|
40,571,696 |
|
|
|
435,142 |
|
|
|
|
|
Philip R. Lochner, Jr. |
|
|
38,724,831 |
|
|
|
2,282,007 |
|
|
|
|
|
Norman C. Payson, M.D. |
|
|
40,571,387 |
|
|
|
435,451 |
|
|
|
|
|
Mahvash Yazdi |
|
|
38,981,995 |
|
|
|
2,024,843 |
|
|
|
|
|
|
|
|
Ratification of the Companys Independent Registered Public Accountants |
|
|
|
|
The Board of Directors appointed Deloitte & Touche LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2008, subject to shareholder approval. The results of
the stockholder voting were as follows: |
|
|
|
|
|
For |
|
|
40,642,462 |
|
Against |
|
|
360,664 |
|
Withhold/Abstentions |
|
|
3,710 |
|
Broker Non-Votes |
|
|
|
|
ITEM 5. OTHER INFORMATION
Late
Filing of Form 10-Q for the Quarter ended June 30, 2008.
In our press release on July 30, 2008, we announced that we were in
the process of evaluating our accounts receivable reserves and on
August 15, 2008 we filed Form 12b-25 requesting an extension on the
filing of our Form 10-Q for the quarter ended June 30, 2008. On
September 8, 2008, we reached final resolution on our accounts receivable
reserves in which we concluded that our accounts receivable reserves
were over-reserved by $1.5 million, or 3.9% of pre-tax net income for the quarter ended
June 30, 2008. In addition, subsequent
to the release of preliminary earnings on July 30, 2008, the Company
identified and recorded a $650,000, or 1.7% of pre-tax net income for
the quarter ended June 30, 2008, warranty obligation relating to replacement
obligations for Medicare equipment required to be transferred to
patients after thirteen months. The net effect of these two items
resulted in a $850,000, or 2.2% of pre-tax net income for the quarter
ended June 30, 2008, increase to the quarters pre-tax net income.
These corrections have been recorded in the quarterly period ended June 30, 2008.
The Company also conducted a review of its accounts receivable reserves
in prior period financial statements and
concluded that none of the prior periods were materially misstated. Therefore,
the Company concluded that no restatement is required for any prior period
as a result of these errors.
42
ITEM 6. EXHIBITS
|
|
|
|
|
Exhibit |
|
|
Number |
|
Reference |
|
|
|
|
|
|
2.1 |
|
|
Agreement and Plan of Merger, dated as of June 18, 2008, by and among the Company, Buyer, and Merger Sub. (a) |
|
|
|
|
|
|
3.1 |
|
|
Apria Healthcare Group Inc. Bylaws, as amended and restated as of February 19, 2008. (b) |
|
|
|
|
|
|
10.1 |
|
|
Credit Agreement, dated as of June 18, 2008, by and among the Company, Lenders, Banc of America Bridge LLC,
Barclays Capital and Wachovia Capital Markets, LLC. (a) |
|
|
|
|
|
|
10.30 |
# |
|
Form of Employee Time-Based Stock Appreciation Rights Award Agreement under the Registrants 2003
Performance Incentive Plan. (c) |
|
|
|
|
|
|
10.31 |
# |
|
Revised Form of Employee Performance-Based Restricted Stock Unit Award Agreement under the Registrants 2003
Performance Incentive Plan. (c) |
|
|
|
|
|
|
10.32 |
# |
|
Registrants 2008 Executive Bonus Plan. (c) |
|
|
|
|
|
|
10.33 |
# |
|
Revised Form of Employee Time-Based Restricted Stock Unit Award Agreement under the Registrants 2003
Performance Incentive Plan. (c) |
|
|
|
|
|
|
31.1 |
|
|
Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a).* |
|
|
|
|
|
|
31.2 |
|
|
Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a).* |
|
|
|
|
|
|
32.1 |
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.* |
|
|
|
|
|
|
32.2 |
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.* |
|
|
|
# |
|
Management contract or compensatory plan or arrangement. |
|
* |
|
Filed Herewith. |
|
(a) |
|
Incorporated by reference to Current Report on Form 8-K dated June 18, 2008, as filed on June
20, 2008. |
|
(b) |
|
Incorporated by reference to Current Report on Form 8-K dated February 19, 2008, as filed on
February 26, 2008. |
|
(c) |
|
Incorporated by reference to Current Report on Form 8-K dated February 29, 2008, as filed on
March 6, 2008. |
43
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
APRIA HEALTHCARE GROUP INC.
Registrant
|
|
|
/s/ CHRIS A. KARKENNY
|
|
|
Chris A. Karkenny |
|
|
Executive Vice President and Chief Financial Officer
(Principal Financial Officer) |
|
|
|
|
|
/s/ PETER A. REYNOLDS
|
|
|
Peter A. Reynolds |
|
|
Chief Accounting Officer and Controller
(Principal Accounting Officer) |
|
September 11, 2008
44
EXHIBIT INDEX
|
|
|
|
|
Exhibit |
|
|
Number |
|
Reference |
|
|
|
|
|
|
2.1 |
|
|
Agreement and Plan of Merger, dated as of June 18, 2008, by and among the Company, Buyer, and Merger Sub. (a) |
|
|
|
|
|
|
3.1 |
|
|
Apria Healthcare Group Inc. Bylaws, as amended and restated as of February 19, 2008. (b) |
|
|
|
|
|
|
10.1 |
|
|
Credit Agreement, dated as of June 18, 2008, by and among the Company, Lenders, Banc of America Bridge LLC,
Barclays Capital and Wachovia Capital Markets, LLC. (a) |
|
|
|
|
|
|
10.30 |
# |
|
Form of Employee Time-Based Stock Appreciation Rights Award Agreement under the Registrants 2003
Performance Incentive Plan. (c) |
|
|
|
|
|
|
10.31 |
# |
|
Revised Form of Employee Performance-Based Restricted Stock Unit Award Agreement under the Registrants 2003
Performance Incentive Plan. (c) |
|
|
|
|
|
|
10.32 |
# |
|
Registrants 2008 Executive Bonus Plan. (c) |
|
|
|
|
|
|
10.33 |
# |
|
Revised Form of Employee Time-Based Restricted Stock Unit Award Agreement under the Registrants 2003
Performance Incentive Plan. (c) |
|
|
|
|
|
|
31.1 |
|
|
Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a).* |
|
|
|
|
|
|
31.2 |
|
|
Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a).* |
|
|
|
|
|
|
32.1 |
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.* |
|
|
|
|
|
|
32.2 |
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.* |
|
|
|
# |
|
Management contract or compensatory plan or arrangement. |
|
* |
|
Filed Herewith. |
|
(a) |
|
Incorporated by reference to Current Report on Form 8-K dated June 18, 2008, as filed on June
20, 2008. |
|
(b) |
|
Incorporated by reference to Current Report on Form 8-K dated February 19, 2008, as filed on
February 26, 2008. |
|
(c) |
|
Incorporated by reference to Current Report on Form 8-K dated February 29, 2008, as filed on
March 6, 2008. |
45